US9693577B2 - Method of preparing a nutritional powder comprising spray dried HMB - Google Patents
Method of preparing a nutritional powder comprising spray dried HMB Download PDFInfo
- Publication number
- US9693577B2 US9693577B2 US14/043,470 US201314043470A US9693577B2 US 9693577 B2 US9693577 B2 US 9693577B2 US 201314043470 A US201314043470 A US 201314043470A US 9693577 B2 US9693577 B2 US 9693577B2
- Authority
- US
- United States
- Prior art keywords
- protein
- calcium
- hmb
- soluble
- nutritional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 144
- 239000000843 powder Substances 0.000 title claims abstract description 144
- 239000007921 spray Substances 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 115
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 115
- 239000011575 calcium Substances 0.000 claims abstract description 98
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 98
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 91
- 239000002738 chelating agent Substances 0.000 claims abstract description 27
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 9
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims abstract description 8
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims abstract description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 7
- 239000010452 phosphate Substances 0.000 claims abstract description 7
- 239000002002 slurry Substances 0.000 claims description 55
- 150000001720 carbohydrates Chemical class 0.000 claims description 35
- 238000001694 spray drying Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000013019 agitation Methods 0.000 claims description 10
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 6
- 239000001508 potassium citrate Substances 0.000 claims description 6
- 229960002635 potassium citrate Drugs 0.000 claims description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 6
- 235000011082 potassium citrates Nutrition 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 5
- 235000019800 disodium phosphate Nutrition 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims 1
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 110
- 235000018102 proteins Nutrition 0.000 description 106
- 239000000203 mixture Substances 0.000 description 33
- 235000014633 carbohydrates Nutrition 0.000 description 31
- 239000007788 liquid Substances 0.000 description 31
- 239000004615 ingredient Substances 0.000 description 29
- 239000003925 fat Substances 0.000 description 27
- 235000019197 fats Nutrition 0.000 description 26
- 239000000047 product Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 17
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 14
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 13
- 229950006137 dexfosfoserine Drugs 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 108010046377 Whey Proteins Proteins 0.000 description 11
- -1 calcium HMB monohydrate Chemical class 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 10
- 235000021119 whey protein Nutrition 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 238000004062 sedimentation Methods 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 7
- 102000014171 Milk Proteins Human genes 0.000 description 7
- 108010011756 Milk Proteins Proteins 0.000 description 7
- 108010033929 calcium caseinate Proteins 0.000 description 7
- 235000021239 milk protein Nutrition 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 235000019486 Sunflower oil Nutrition 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 229940080237 sodium caseinate Drugs 0.000 description 5
- 239000002600 sunflower oil Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 230000004845 protein aggregation Effects 0.000 description 4
- 229940001941 soy protein Drugs 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 108010084695 Pea Proteins Proteins 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 244000290333 Vanilla fragrans Species 0.000 description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 229940071162 caseinate Drugs 0.000 description 3
- 235000014651 chocolate spreads Nutrition 0.000 description 3
- 229960004874 choline bitartrate Drugs 0.000 description 3
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000019221 dark chocolate Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000019702 pea protein Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000001509 sodium citrate Chemical class 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical class O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RWBRUCCWZPSBFC-UHFFFAOYSA-N 17-(1-hydroxyethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 RWBRUCCWZPSBFC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A23L1/30—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/46—Spray-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present disclosure relates generally to nutritional powders and more particularly to nutritional powders comprising spray dried beta-hydroxy-beta-methylbutyrate (HMB).
- HMB spray dried beta-hydroxy-beta-methylbutyrate
- Beta-hydroxy-beta-methylbutyrate is a naturally occurring amino acid metabolite that is known for use in a variety of nutritional products and supplements. HMB is commonly used in such products to help build or maintain healthy muscle in selected individuals.
- HMB is a metabolite of the essential amino acid leucine and has been shown to modulate protein turnover and inhibit proteolysis. In most individuals, muscle converts approximately 5% of available leucine to HMB, thus producing about 0.2 to about 0.4 grams of HMB per day in a 70 kg male. In studies where various kinds of stress were induced in animals, HMB supplementation increased lean mass. Clinical studies also suggest that HMB has at least two functions in recovery from illness or injury including protection of lean mass from stress-related damage and enhancement of protein maintenance or synthesis. It has been suggested that HMB may also be useful for enhancing immune function, reducing the incidence or severity of allergy or asthma, reducing total serum cholesterol and low density lipoprotein cholesterol, increasing the aerobic capacity of muscle, and other uses.
- HMB is most often administered to individuals to support the development and maintenance of muscle mass and strength
- many HMB products have been formulated with additional nutrients that may also be helpful in promoting healthy muscle.
- Some of these HMB products contain additional nutrients such as fat, carbohydrate, protein, vitamins, minerals and so forth.
- Calcium HMB is a commonly used form of HMB when formulated in oral nutritional products, which products include tablets, capsules, reconstitutable powders, and nutritional liquids and emulsions.
- Reconstitutable powders are particularly useful in this regard because such powders are often more shelf-stable than their liquid counterparts for extended periods even when formulated with multiple ingredients such as amino acids, carbohydrates, protein, and fat. These powders, however, often give off an undesirable aroma or odor, which is especially pronounced in the headspace of packaged product immediately after opening prior to use.
- One technique for preparing such nutritional powders is spray drying the powder. This technique involves preparing a liquid or a slurry of the nutritional composition, and spray drying the liquid or slurry to form the nutritional powder.
- This technique involves preparing a liquid or a slurry of the nutritional composition, and spray drying the liquid or slurry to form the nutritional powder.
- the presence of calcium HMB creates stability issues in the liquids or slurries used in the preparation of the powders.
- the calcium will disassociate from the HMB and interact with the protein present in the formulation, resulting in protein aggregation and sedimentation in the slurry.
- the protein aggregation and sedimentation is especially troubling for the production of a spray dried nutritional powder, as the protein aggregation and sedimentation can clog the spray drying equipment and, at the very least, require more frequent maintenance and cleaning of the equipment, which would have the effect of increasing manufacture time and costs.
- One embodiment of the present disclosure is directed to a nutritional powder comprising HMB and at least one of protein, carbohydrate, and fat, wherein at least a portion of the HMB is spray dried in combination with at least a portion of at least one of the protein, carbohydrate, and fat in the nutritional powder.
- Another embodiment of the present disclosure is directed to a nutritional powder comprising from about 0.1% to about 8% HMB, from about 5% to about 70% protein, from about 10% to about 75% carbohydrate, and from about 20% to about 85% fat, all by weight of the nutritional powder, wherein least a portion of the HMB is spray dried with at least a portion of at least one of the protein, the carbohydrate, and the fat in the composition.
- Another embodiment of the present disclosure is directed to a method of preparing a nutritional powder comprising spray dried HMB.
- the method comprises preparing a liquid composition comprising HMB and at least one of protein, carbohydrate, and fat, and then spray drying the liquid composition to produce a nutritional powder having improved sensory properties.
- Another embodiment of the present disclosure is directed to a nutritional powder comprising soluble calcium, protein, and at least one chelating agent selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof. At least a portion of the soluble calcium is calcium HMB. At least a portion of the protein is soluble protein. The powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1. The calcium HMB, the protein, and the at least one chelating agent are spray dried together in accordance with this embodiment.
- Another embodiment of present disclosure is directed to a method of preparing a nutritional powder comprising spray dried calcium HMB.
- the method comprises preparing an aqueous slurry by admixing at least one chelating agent followed by soluble calcium to water. At least a portion of the soluble calcium is calcium HMB, and the at least one chelating agent is selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof.
- the method also includes holding the aqueous slurry under agitation for at least 10 minutes; admixing protein to the aqueous slurry, where at least a portion of the protein is soluble protein; and spray drying the aqueous slurry to produce the nutritional powder.
- the nutritional powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1.
- the method further comprises admixing carbohydrate to the aqueous slurry prior the addition of the protein. Additionally, in accordance with this and other embodiments, the method further comprises admixing fat into the aqueous slurry after the addition of the carbohydrate but prior to spray drying.
- the nutritional powders comprise spray dried HMB and other nutrients. These and other exemplary features of the nutritional powders, including methods of making such powders, as well as some of the many optional variations and additions thereof, are described in detail hereafter.
- HMB refers to beta-hydroxy-beta-methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid) and sources thereof. All weights, percentages, and concentrations as used herein to characterize HMB are based on the weight of HMB, except that all weights, percentages, and concentrations as used herein to characterize calcium HMB are based on the weight of calcium HMB monohydrate, unless otherwise specified.
- nutritional powder refers to nutritional powders comprising HMB and at least one of protein, carbohydrate, and fat, which are reconstitutable with an aqueous liquid, and which are suitable for oral administration to a human.
- fat and “oil” as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals.
- the various embodiments of the nutritional powders of the present disclosure may also be substantially free of any optional or selected essential ingredient or feature described herein, provided that the remaining nutritional powder still contains all of the required ingredients or features as described herein.
- the term “substantially free” means that the selected nutritional powder contains less than a functional amount of the optional ingredient, typically less than about 0.5%, including less than about 0.1%, and also including zero percent, by weight of such optional or selected essential ingredient.
- the nutritional powders and corresponding manufacturing methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements of the disclosure as described herein, as well as any additional or optional element described herein or otherwise useful in nutritional powder formula applications.
- the nutritional powders are typically in the form of flowable or substantially flowable particulate compositions, or at least particulate compositions that can easily be scooped and measured with a spoon or similar other device, wherein the compositions can easily be reconstituted by the intended user with a suitable aqueous liquid, typically water, to form a liquid nutritional formulation for immediate oral or enteral use.
- a suitable aqueous liquid typically water
- immediate oral or enteral use generally means within about 48 hours, most typically within about 24 hours, preferably right after reconstitution.
- the nutritional powders are produced by spray drying.
- the nutritional powders may be formulated with sufficient kinds and amounts of nutrients so as to provide a sole, primary, or supplemental source of nutrition, or to provide a specialized nutritional powder for use in individuals afflicted with specific diseases or conditions.
- the nutritional powder may be formulated for use with individuals for maintaining or building muscle mass.
- the nutritional powders may be reconstituted with water prior to use to a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the powders are reconstituted with water to form compositions comprising from about 100 kcal to about 500 kcal per 240 ml, including from about 150 to about 350 kcal per 240 ml, and also including from about 200 kcal to about 320 kcal per 240 ml.
- the amount of calcium HMB in the reconstituted liquids most typically ranges from about 0.4 g per 240 ml to about 3 g per 240 ml, including from about 0.75 g per 240 ml to about 2 g per 240 ml, and including about 1.5 g per 240 ml.
- serving size for the reconstituted nutritional liquid can vary depending upon a number of variables, a typical serving size ranges from about 100 ml to about 300 ml, including from about 150 ml to about 250 ml, and including from about 190 ml to about 240 ml.
- the nutritional powders comprise at least one of protein, carbohydrate, and fat.
- the nutritional powders comprise protein.
- at least a portion of the protein is soluble protein.
- the nutritional powders disclosed herein include protein and at least one of carbohydrate and fat.
- any source of protein, carbohydrate, and fat that is known or otherwise suitable for use in nutritional products may be suitable for use herein, provided that such macronutrients are also compatible with the essential elements and other desired properties of the nutritional powders as defined herein.
- Protein concentrations may range from 0 to about 90%, including from about 5% to about 75%, including from about 8% to about 50%, and also including from about 12% to about 30%, by weight of the nutritional powder.
- Carbohydrate concentrations may range from 0 to about 99%, including from about 20% to about 90%, including from about 30% to about 80%, and also including from about 40% to about 70%, by weight of the nutritional powder.
- Fat concentrations in the nutritional powders may range from 0 to about 99%, including from about 5% to about 75%, including from about 10% to about 35%, and also including from about 15% to about 20%, by weight of the nutritional powder.
- the range or level of protein, carbohydrate, and fat in the nutritional powders may also be characterized in addition to or in the alternative as a percentage of total calories in the nutritional powder as set forth in the following table.
- Embodiment B Embodiment C Embodiment A (% of Total (% of Total Nutrient (% of Total Calories) Calories) Protein 1-98 5-70 15-35 Carbohydrate 1-98 10-75 30-50 Fat 1-98 20-85 35-55
- Non-limiting examples of suitable protein or sources thereof for use in the nutritional powders include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, which may be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy, potato, pea) or combinations thereof.
- milk e.g., casein, whey
- animal e.g., meat, fish
- cereal e.g., rice, corn
- vegetable e.g., soy, potato, pea
- Non-limiting examples of such proteins include whey protein concentrates, whey protein isolates, whey protein hydrolysates, acid caseins, sodium caseinates, calcium caseinates, potassium caseinates, casein hydrolysates, milk protein concentrates, milk protein isolates, milk protein hydrolysates, nonfat dry milk, whole cow's milk, partially or completely defatted milk, condensed skim milk, soy protein concentrates, soy protein isolates, soy protein hydrolysates, pea protein concentrates, pea protein isolates, pea protein hydrolysates, collagen proteins, potato proteins, collagen proteins, and combinations thereof.
- Non-limiting examples of suitable carbohydrates or sources thereof for use in the nutritional powders include maltodextrin, hydrolyzed or modified starch or cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrates, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), and combinations thereof.
- Non-limiting examples of suitable fats or sources thereof for use in the nutritional powders include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, and combinations thereof.
- soluble protein refers to those proteins having a solubility of at least about 90% as measured in accordance with a Protein Solubility Measurement Test that includes the following steps: (1) suspend the protein at 2.00% (w/w) in water; (2) stir vigorously for one hour at 20° C. to form a suspension; (3) remove an aliquot of the suspension, and determine protein concentration as total protein; (4) centrifuge the suspension at 31,000 rpm and at 20° C. for one hour; (5) determine the protein concentration in the supernatant (the soluble protein); and (6) express the soluble protein as a percentage of the total protein.
- the soluble protein may represent from about 50% to 100%, including from 55% to 100%, including from about 60% to about 100%, including from about 40% to about 85%, including from about 60% to about 80%, and also including from about 65% to about 75%, by weight of the total protein in the nutritional powder.
- the concentration of soluble protein may range from at least about 0.5%, including from about 0.5% to about 26%, including about 1% to about 26%, and also including from about 2% to about 15%, also including from about 3% to about 10%, and also including from about 4% to about 8%, by weight of the nutritional powder.
- the amount of soluble protein included in the nutritional powder may also be characterized as a weight ratio of soluble protein to calcium HMB, where the nutritional powder includes a weight ratio of soluble protein to calcium HMB of at least about 3, including from about 3 to about 12, including from about 4 to about 12, also including from about 6.1 to about 12, also including from about 7 to about 11, and also including from about 8 to about 10.
- any soluble protein source is suitable for use herein provided that it meets the solubility requirement as defined herein.
- suitable soluble protein includes sodium caseinate (>95% solubility as determined by the Protein Solubility Measurement Test), whey protein concentrate (>90% solubility as determined by the Protein Solubility Measurement Test), calcium caseinate (>95% solubility as determined by the Protein Solubility Measurement Test), milk protein isolate (>95% solubility as determined by the Protein Solubility Measurement Test), and combinations thereof.
- non-soluble proteins may also be included in the nutritional powders provided that the soluble protein component is represented in accordance with the requirements as set forth herein.
- Soluble protein suitable for use herein may also be characterized by the content of phosphoserine in the protein, wherein the soluble proteins in this context are defined as those proteins having at least about 100 mmoles, including from about 150 to about 400 mmoles, including from about 200 to about 350 mmoles, and also including from about 250 to about 350 mmoles, of phosphoserine per kilogram of protein.
- the weight ratio of the soluble protein (with the defined phosphoserine content) to the calcium HMB may be at least about 3:1, including at least about 5:1, and also including at least about 7:1, and also including from about 9:1 to about 30:1.
- the proteins having the requisite content of phosphoserine are most typically in the form of monovalent caseinate salts such as sodium caseinate, calcium caseinate, potassium caseinate, and combinations thereof.
- the soluble protein may also be characterized by a mole ratio of monovalent caseinate phosphoserine to calcium HMB monohydrate of least about 0.2, including from about 0.2 to about 2, and also including from about 0.25 to about 1.7.
- any phosphoserine-containing protein may be suitable for use herein provided that it has the requisite phosphoserine content and that the phosphoserine used in calculating the ratios are not bound, complexed, or otherwise attached to a polyvalent cation such as calcium or magnesium.
- soluble proteins may include proteins that have little or no phosphoserine content, so that the soluble protein fraction of the compositions may include soluble protein with or without phosphoserine.
- the soluble protein for use herein may therefore be defined by any one or more of the soluble protein characterizations, separately or in combination.
- the phosphoserine moieties within the protein may therefore be available for binding with the calcium released from the calcium HMB so that the above ratios of soluble protein to calcium HMB are the ratio of protein with phosphoserine moities that are unbound, unattached, or otherwise available to bind soluble calcium from the calcium HMB during formulation. It could be, for example, that a mixture of calcium caseinate and sodium caseinate are used in the composition, but the ratio of proteins defined by a phosphoserine content to calcium HMB is calculated based on the protein fraction from the sodium caseinate and additionally any protein from the calcium caseinate fraction that is not bound to calcium.
- the HMB component of the nutritional powders may be obtained from any HMB source suitable for use in a nutritional product.
- HMB sources include HMB as a free acid, a salt, an anhydrous or hydrated salt, an ester, a lactone, or other forms that otherwise provide a bioavailable form of HMB for the nutritional powder.
- HMB sources include HMB salts, hydrated or anhydrous, of sodium, potassium, magnesium, chromium, calcium, or other non-toxic salt forms.
- Calcium HMB is used in accordance with certain embodiments disclosed herein, and is most typically formulated or otherwise obtained as calcium HMB monohydrate, a commercially available source of which is available from Technical Sourcing International (TSI) of Salt Lake City, Utah USA.
- the total concentration of HMB in the nutritional powders may range up to about 10%, including from about 0.1% to about 10%, including from about 0.1% to about 8%, and also including from about 0.2% to about 5.0%, and also including from about 0.3% to about 3%, and also including from about 0.4% to about 1.5%, by weight of the nutritional powder.
- concentrations may represent the concentration of HMB or the HMB source for use in the composition.
- the total concentration of calcium HMB (e.g., calcium HMB monohydrate) in the nutritional powders may range up to about 10%, including from about 0.1% to about 10%, including from about 0.1% to about 8%, and also including from about 0.2% to about 5.0%, and also including from about 0.3% to about 3%, and also including from about 0.4% to about 1.5%, by weight of the nutritional powder.
- calcium HMB e.g., calcium HMB monohydrate
- HMB including but not limited to calcium HMB
- used in the preparation of the final nutritional powder is in the form of spray dried calcium HMB, as described herein.
- the nutritional powders disclosed herein include at least one chelating agent.
- the presence of calcium HMB in the formulation used to produce the nutritional powder can adversely affect the manufacture and production of spray dried powders.
- the presence of the calcium HMB in the formulation will tend to cause protein present in the formulation to aggregate or form sediment, as a result of disassociated calcium from the calcium HMB interacting with the protein.
- the aggregation and sedimentation of the protein prompts the need for more frequent cleaning and maintenance of the spray drying equipment, as the aggregation and sedimentation may cause the equipment to operate less efficiently, and in some instances clog.
- the presence of the chelating agent in the formulations of the nutritional powders disclosed herein can reduce or minimize the aforementioned physical stability issues caused by the presence of the calcium HMB in the nutritional powders containing protein.
- the chelating agents are effective to minimize or reduce the aggregation and sedimentation during the production of the spray dried nutritional powder when the chelating agent and the calcium HMB are given time to chelate prior to the introduction of protein to the formulation. Accordingly, as discussed in greater detail below, the chelating agent and the calcium HMB are introduced into the slurry used to prepare the spray dried nutritional powder and held for at least 10 minutes prior to introduction of the protein into such slurry.
- Nonlimiting examples of suitable chelating agents for use in the nutritional powders disclosed herein include citrates and phosphates.
- soluble citrates include, but are not limited to, alkali metal salts of citrates, such as potassium citrate, and sodium citrate.
- soluble phosphates include, but are not limited to, alkali metal salts of phosphates, such as dipotassium phosphate, disodium phosphate (commonly available in anhydrous form), and the like, and alkali earth metal salts of phosphates, such as tricalcium phosphate.
- the weight ratio of SCBC to the concentration of total soluble calcium can be adjusted to minimize the concentration of unbound (disassociated) calcium that is present in the slurry that is used during the spray drying of the powder, or to minimize the weight ratio of such unbound (disassociated) calcium to HMB in the slurry. This adjustment improves the slurry's physical stability, and consequently minimizes or reduces the production issues associated with spray drying nutritional product comprising calcium HMB.
- the ratio of the soluble calcium binding capacity, as defined above, to total soluble calcium of the nutritional emulsions is a weight ratio of at least about 2.3, including from about 2.3 to about 12.0, also including from about 3.0 to about 8.0, and also including from about 4.0 to about 6.5.
- the nutritional powders of the present disclosure comprise soluble calcium as a desirable ingredient to facilitate developing or maintaining of healthy muscle in targeted individuals.
- soluble calcium refers to the equivalents of ionized or supernatant calcium in the slurry used to prepare the spray dried powder as measured at 20° C. At least a portion of the soluble calcium is provided by calcium HMB as described herein. Any other calcium source, however, may be used provided that such other source is compatible with the essential other ingredients of the nutritional powders disclosed herein as well as compatible with the requirements set forth by the ratio of SCBC to total calcium as described above.
- the calcium in the nutritional powders may also be characterized by a ratio (on an equivalents basis) of soluble citrate to soluble calcium of not more than 5, including not more than 4, also including not more than 3, and also including from about 0.8 to about 3.
- soluble citrate refers to the equivalents of citrate cations, respectively, present in supernatants of the nutritional slurry as measured at 20° C.
- the weight ratio of calcium HMB to the soluble calcium ranges from about 6:1 to about 15:1, including from about 6:1 to about 12:1, also including from about 6:1 to about 10:1, and also including from about 6:1 to about 8:1.
- the nutritional powders may further comprise vitamin D to help maintain healthy muscle in the targeted user.
- Vitamin D forms include Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol) or other forms suitable for use in a nutritional product.
- the amount of Vitamin D in the nutritional powder typically ranges up to about 1000 IU, including from about 10 IU to about 600 IU, and also including from about 50 IU to about 400 IU per serving size as described herein.
- the nutritional powders may further comprise other optional ingredients that may modify the physical, chemical, hedonic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population.
- optional ingredients are known or otherwise suitable for use in other nutritional products and may also be used in the nutritional powders described herein, provided that such optional ingredients are suitable for oral administration and are compatible with the essential ingredients in the nutritional powders.
- Non-limiting examples of such optional ingredients include preservatives, antioxidants, emulsifying agents, buffers, pharmaceutical actives, additional nutrients as described herein, colorants, flavors, thickening agents, stabilizers, and masking agents, and combinations thereof.
- the nutritional powders may further comprise vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B12, carotenoids, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts, and derivatives thereof, and combinations thereof.
- vitamins or related nutrients include vitamin A, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B12, carotenoids, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts, and derivatives thereof, and combinations thereof.
- the nutritional powders may further comprise minerals, non-limiting examples of which include phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, selenium, chloride, and combinations thereof.
- the nutritional powders are reconstituted with water or other suitable liquid to provide a nutritional liquid.
- suitable liquid to provide a nutritional liquid.
- Such liquids from the powders described herein are useful in methods of providing supplemental, primary, or sole sources of nutrition, or in methods of providing individuals one or more benefits as described herein.
- the liquids may be administered orally as needed to provide the desired level of nutrition, most typically in the form of one to two servings daily, in one or more divided doses daily.
- serving sizes typically ranging from about 100 ml to about 300 ml, including from about 150 ml to about 250 ml, and including from about 190 ml to about 240 ml, wherein each serving contains from about 0.4 g to about 3.0 g, including from about 0.75 g to about 2.0 g, and including about 1.5 g, of calcium HMB per serving.
- Such methods are further directed to providing individuals upon administration of such products, most typically after daily use over an extended period of time of from about 1 month to about 6 months, including from about 1 month to about 3 months, one or more of 1) supporting maintenance of lean body mass, 2) supporting of strength, muscle strength or both, 3) decreasing protein breakdown and damage of muscle cells, and 4) helping with muscle recovery following exercise or other trauma, and 5) reducing muscle protein breakdown following exercise.
- Such methods are also helpful to achieve one or more of 1) maintaining and supporting lean body mass in elderly with sarcopenia, 2) providing nutrition to support an active and independent lifestyle in individuals, especially in the elderly, 3) supporting recovery of muscle strength, 4) helping rebuild muscle and regain strength, and 5) improving strength, including muscle strength, and mobility.
- the nutritional powders may be prepared by any collection of known or otherwise effective techniques, suitable for making and formulating a nutritional powder provided that the techniques include or are modified to include a spray drying step to provide the powder with the requisite spray dried HMB ingredient.
- the spray drying step may likewise include any spray drying technique that is known for or otherwise suitable for use in the production of nutritional powders. Many different spray drying methods and techniques are known for use in the nutrition field, all of which may be suitable for use in the manufacture of the nutritional powders herein.
- One method of preparing the nutritional powder comprises forming an aqueous slurry or liquid comprising HMB and at least one of protein, carbohydrate, and fat, and then spray drying the slurry or liquid to produce a spray dried nutritional powder comprising spray dried HMB and having improved sensory properties.
- the method may further comprise the step of spray drying, dry mixing (also known as dry blending), or otherwise adding additional nutritional ingredients, including any one or more of the ingredients described herein, to the spray dried nutritional powder.
- the methods of manufacture are formulated with calcium HMB, which is most typically formulated as calcium HMB monohydrate, as the HMB source for use in the methods.
- the nutritional powders for spray drying are formulated with calcium HMB
- the nutritional powders are formulated with at least one chelating agent in the following manner so as to minimize or avoid the aggregation and sedimentation issues associated with the use of calcium HMB.
- the chelating agents are admixed into an aqueous slurry or liquid.
- the calcium HMB is then admixed to the aqueous slurry or liquid containing the chelating agents.
- the aqueous slurry or liquid containing the chelating agents and the calcium HMB are then held for at least 10 minutes under agitation, so to allow the disassociated or unbound calcium from the calcium HMB to chelate with the chelating agents in the slurry or liquid.
- the protein of which at least a portion is soluble protein as discussed herein, is admixed into the aqueous slurry or liquid.
- the at least a portion of the carbohydrates is added before the protein is added to the slurry. Any other portion of carbohydrates may be dry mixed into the nutritional powder following spray drying.
- the fat when fat is present in the formulation of the nutritional powder, the fat is added after the protein and any carbohydrate are added, but before spray drying.
- At least three separate slurries are prepared, including a protein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MN) slurry, and a protein-in-water (PIW) slurry.
- PIF protein-in-fat
- CHO-MN carbohydrate-mineral
- PIW protein-in-water
- the PIF slurry is formed by heating and mixing the selected oils (e.g., canola oil, corn oil) to a specified temperature and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate) with continued heat and agitation.
- an emulsifier e.g., lecithin
- fat soluble vitamins e.g., lecithin
- a portion of the total protein e.g., milk protein concentrate
- the CHO-MN slurry is formed by adding with heated agitation to water: minerals (e.g., potassium citrate, dipotassium phosphate, sodium citrate), trace and ultra trace minerals (TM/UTM premix), thickening or suspending agents (e.g., gellan, carrageenan), and calcium HMB and any additional other HMB source.
- minerals e.g., potassium citrate, dipotassium phosphate, sodium citrate
- TM/UTM premix trace and ultra trace minerals
- thickening or suspending agents e.g., gellan, carrageenan
- calcium HMB and any additional other HMB source e.g., calcium HMB and any additional other HMB source.
- the heated agitation occurs at a specified temperature range.
- the resulting CHO-MIN slurry is held for 10 minutes with continued heat and agitation before adding any additional minerals (e.g., potassium chloride, magnesium carbonate, potassium iodide) and any carbohydrates (e.g., fr
- the resultant slurries are then blended together with heated agitation, at a specified temperature range, and the pH adjusted to the desired range, typically from 6.6-7.0, after which the composition is subjected to high-temperature short-time (HTST) processing during which the composition is heat treated as is known in the art, emulsified and homogenized.
- HTST high-temperature short-time
- Water soluble vitamins and ascorbic acid are added, the pH is again adjusted to the desired range if necessary, flavors are added, and water is added to achieve the desired total solid level.
- the resultant slurry is then subjected to spray drying to form the nutritional powder.
- a method is directed to the preparation of a nutritional powder comprising spray dried HMB.
- the method includes preparing an aqueous slurry by admixing at least one chelating agent followed by soluble calcium to water. At least a portion of the soluble calcium is calcium HMB, and the at least one chelating agent is selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof.
- the method also includes holding the aqueous slurry under agitation for at least 10 minutes; admixing protein to the aqueous slurry, where at least a portion of the protein is soluble protein; and spray drying the aqueous slurry to produce the nutritional powder.
- the nutritional powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1.
- the method further comprises admixing carbohydrate to the aqueous slurry prior the addition of the protein. Additionally, in accordance with the preceding and other embodiments, the method further comprises admixing fat into the aqueous slurry after the addition of the protein and any carbohydrate but prior to spray drying.
- all of the HMB in the nutritional powder is spray dried as described herein, including from about 50% to about 100%, by weight of the nutritional powder is spray dried as well.
- most or all of the ingredients in the nutritional powder, including all of the HMB in the powder are spray dried together to form a spray dried nutritional powder wherein 100% of the HMB is therefore spray dried HMB.
- a portion of the HMB in the nutritional powder may be spray dried with some or all of at least one of the protein, carbohydrate, and/or the fat in the nutritional powder, including from about 20% to about 90%, also including from about 40% to about 90%, and also including from about 50% to about 80%, by weight of the total HMB as spray dried HMB.
- a portion of the HMB may be non-spray dried and thus represent from about 10% to about 80%, including from about 10% to about 60%, and also including from about 20% to about 50%, by weight of the total HMB in the nutritional powder.
- the nutritional powders are preferably spray dried to a moisture content of less than about 3.0%, most typically from about 1.0% to about 2.8%, by weight of the finished powder.
- the exemplified compositions are nutritional powders prepared in accordance with the manufacturing methods described herein, such that each exemplified nutritional powder comprising spray dried HMB has minimal or no protein aggregation or sedimentation issues associated with the calcium HMB, along with minimal or no off odors when packaged in sealed containers, and then a portion of which is later removed and reconstituted with water to the desired caloric density to form a nutritional liquid containing 1.5 g of calcium HMB monohydrate per 240 ml of reconstituted liquid.
- the 240 ml liquid represents a single serving suitable for oral administration within 48 hours following such constitution.
- each of the exemplified compositions can be manufactured by 1) preparing a first liquid slurry (CHO/MIN) comprising adding chelating agents, followed by calcium HMB monohydrate and any minerals to water, then after a 10 minute hold time, adding the carbohydrates, and, 2) preparing a second liquid slurry comprising oils, stabilizers, oil soluble vitamins, and protein (PIF), 3) preparing a third liquid slurry comprising protein an water (PIW), 4) blending the first and second slurries together, and then blending the resulting slurry with the third slurry, 5) subjecting the resulting blend to homogenization and heat treatment, 6) standardizing the resulting homogenized blend with vitamins, flavors, trace and ultra trace minerals, and other heat sensitive ingredients, and then 7) spray drying the standardized blend to form a spray dried nutritional powder.
- the spray dried powder is then package and hermetically sealed in appropriate containers suitable for long term storage prior to use, during which the product may be opened and product reconstituted to form a nutritional liquid and
- Examples 1-4 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kilogram per 1000 kilogram batch of product, unless otherwise specified.
- Example 1 Example 2
- Example 3 Whey Protein 282.051 293.892 289.892 284.892 Concentrate Calcium Caseinate 192.308 192.308 192.308 Maltodextrin 165.416 165.416 165.416 165.416 Milk Protein Isolate 138.782 138.782 138.782 Cocoa 76.932 76.932 76.932 76.932 Sunflower Oil Creamer 21.474 21.474 21.474 Oil Preblend 19.231 19.231 19.231 19.231 19.231 19.231 19.231 19.231 Chocolate Cream 15.256 15.256 15.256 15.256 Calcium HMB 13.157 1.316 5.316 10.316 Monohydrate Oat Fiber 10.897 10.897 10.897 Tricalcium Phosphate 8.526 8.526 8.526 Vitamin Mineral 8.462 8.462 8.462 8.462 Preblend Dipotassium Phosphate 8.333 8.333 8.333 Rich Dark Chocolate 7.051 7.051 7.051 Carrageenan 6.474
- Examples 5-8 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
- Example 5 Example 6
- Example 7 Example 8 Whey Protein 280.051 272.051 262.051 232.051 Concentrate Calcium Caseinate 192.308 192.308 192.308 192.308 Maltodextrin 165.416 165.416 165.416 165.416 Milk Protein Isolate 138.782 138.782 138.782 Cocoa 76.932 76.932 76.932 76.932 Sunflower Oil Creamer 21.474 21.474 21.474 Oil Preblend 19.231 19.231 19.231 19.231 19.231 19.231 19.231 Chocolate Cream 15.256 15.256 15.256 15.256 Calcium HMB 15.157 25.157 35.157 50.157 Monohydrate Oat Fiber 10.897 10.897 10.897 10.897 Tricalcium Phosphate 8.526 8.526 8.526 Vitamin Mineral 8.462 8.462 8.462 8.462 Preblend Dipotassium Phosphate 8.333 7.051 7.051 7.051 Rich Dark Chocolate 7.051 7.051 7.051 7.051 Carrageen
- Examples 9-12 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
- Example Example Example Example Ingredient Example 9 10 11 12 Whey Protein 235.051 230.051 225.051 216.051 Concentrate Calcium Caseinate 192.308 192.308 192.308 192.308 Maltodextrin 165.416 165.416 165.416 165.416 Milk Protein Isolate 138.782 138.782 138.782 Dutch Cocoa 76.932 76.932 76.932 76.932 Sunflower Oil Creamer 21.474 21.474 21.474 Oil Preblend 19.231 19.231 19.231 19.231 19.231 19.231 19.231 Chocolate Cream 15.256 15.256 15.256 15.256 Calcium HMB 60.157 65.157 70.157 79.157 Monohydrate Oat Fiber 10.897 10.897 10.897 10.897 Tricalcium Phosphate 8.526 8.526 8.526 8.526 Vitamin Mineral 8.462 8.462 8.462 8.462 Preblend Dipotassium Phosphate 8.333 8.333 8.333 Rich Dark Chocolate 7.051 7.051 7.051 Carrageen
Abstract
Spray dried nutritional powders include soluble calcium, protein, and at least one of a soluble citrate, a soluble phosphate, and combinations thereof as at least one chelating agent. At least a portion of the soluble calcium is calcium HMB. At least a portion of the protein is soluble protein. The spray dried nutritional powders have a weight ratio of soluble calcium binding capacity to total soluble calcium of from about 2.3:1 to about 12:1. The calcium HMB, the at least one chelating agent, and the protein are spray dried together.
Description
This application is a continuation-in-part of, claims priority to, and any other benefit of, U.S. application Ser. No. 13/016,041, filed Jan. 28, 2011, now abandoned, which claims priority to and any other benefit of U.S. Provisional Application Ser. No. 61/299,632, filed Jan. 29, 2010, the entire disclosures of both applications being incorporated herein in their entirety by reference.
The present disclosure relates generally to nutritional powders and more particularly to nutritional powders comprising spray dried beta-hydroxy-beta-methylbutyrate (HMB).
Beta-hydroxy-beta-methylbutyrate (HMB) is a naturally occurring amino acid metabolite that is known for use in a variety of nutritional products and supplements. HMB is commonly used in such products to help build or maintain healthy muscle in selected individuals.
HMB is a metabolite of the essential amino acid leucine and has been shown to modulate protein turnover and inhibit proteolysis. In most individuals, muscle converts approximately 5% of available leucine to HMB, thus producing about 0.2 to about 0.4 grams of HMB per day in a 70 kg male. In studies where various kinds of stress were induced in animals, HMB supplementation increased lean mass. Clinical studies also suggest that HMB has at least two functions in recovery from illness or injury including protection of lean mass from stress-related damage and enhancement of protein maintenance or synthesis. It has been suggested that HMB may also be useful for enhancing immune function, reducing the incidence or severity of allergy or asthma, reducing total serum cholesterol and low density lipoprotein cholesterol, increasing the aerobic capacity of muscle, and other uses.
Since HMB is most often administered to individuals to support the development and maintenance of muscle mass and strength, many HMB products have been formulated with additional nutrients that may also be helpful in promoting healthy muscle. Some of these HMB products contain additional nutrients such as fat, carbohydrate, protein, vitamins, minerals and so forth. Calcium HMB is a commonly used form of HMB when formulated in oral nutritional products, which products include tablets, capsules, reconstitutable powders, and nutritional liquids and emulsions. Reconstitutable powders are particularly useful in this regard because such powders are often more shelf-stable than their liquid counterparts for extended periods even when formulated with multiple ingredients such as amino acids, carbohydrates, protein, and fat. These powders, however, often give off an undesirable aroma or odor, which is especially pronounced in the headspace of packaged product immediately after opening prior to use.
There is therefore a need for nutritional powders comprising HMB that are substantially free of undesirable aromas and off odors, especially when packaged and stored for extended periods.
One technique for preparing such nutritional powders is spray drying the powder. This technique involves preparing a liquid or a slurry of the nutritional composition, and spray drying the liquid or slurry to form the nutritional powder. However, the presence of calcium HMB creates stability issues in the liquids or slurries used in the preparation of the powders. In particular, in such liquids or slurries, the calcium will disassociate from the HMB and interact with the protein present in the formulation, resulting in protein aggregation and sedimentation in the slurry. The protein aggregation and sedimentation is especially troubling for the production of a spray dried nutritional powder, as the protein aggregation and sedimentation can clog the spray drying equipment and, at the very least, require more frequent maintenance and cleaning of the equipment, which would have the effect of increasing manufacture time and costs.
Accordingly, there exists a need to minimize or reduce the stability issues that occur during the preparation of spray dried nutritional powders containing calcium HMB.
It has now also been found that the undesirable aromas or odors from nutritional powders comprising HMB can be minimized or eliminated by formulating the nutritional powders with spray dried HMB, wherein the HMB is spray dried with at least a portion of at least one of the protein, the carbohydrate, and the fat in the composition.
One embodiment of the present disclosure is directed to a nutritional powder comprising HMB and at least one of protein, carbohydrate, and fat, wherein at least a portion of the HMB is spray dried in combination with at least a portion of at least one of the protein, carbohydrate, and fat in the nutritional powder.
Another embodiment of the present disclosure is directed to a nutritional powder comprising from about 0.1% to about 8% HMB, from about 5% to about 70% protein, from about 10% to about 75% carbohydrate, and from about 20% to about 85% fat, all by weight of the nutritional powder, wherein least a portion of the HMB is spray dried with at least a portion of at least one of the protein, the carbohydrate, and the fat in the composition.
Another embodiment of the present disclosure is directed to a method of preparing a nutritional powder comprising spray dried HMB. The method comprises preparing a liquid composition comprising HMB and at least one of protein, carbohydrate, and fat, and then spray drying the liquid composition to produce a nutritional powder having improved sensory properties.
It has now also been found that issues relating to physical stability during the preparation of the spray dried nutritional powder comprising calcium HMB can be minimized or eliminated through the use of the at least one chelating agent in combination with calcium HMB as disclosed herein.
Another embodiment of the present disclosure is directed to a nutritional powder comprising soluble calcium, protein, and at least one chelating agent selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof. At least a portion of the soluble calcium is calcium HMB. At least a portion of the protein is soluble protein. The powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1. The calcium HMB, the protein, and the at least one chelating agent are spray dried together in accordance with this embodiment.
Another embodiment of present disclosure is directed to a method of preparing a nutritional powder comprising spray dried calcium HMB. The method comprises preparing an aqueous slurry by admixing at least one chelating agent followed by soluble calcium to water. At least a portion of the soluble calcium is calcium HMB, and the at least one chelating agent is selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof. The method also includes holding the aqueous slurry under agitation for at least 10 minutes; admixing protein to the aqueous slurry, where at least a portion of the protein is soluble protein; and spray drying the aqueous slurry to produce the nutritional powder. The nutritional powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1. In accordance with this and other embodiments, the method further comprises admixing carbohydrate to the aqueous slurry prior the addition of the protein. Additionally, in accordance with this and other embodiments, the method further comprises admixing fat into the aqueous slurry after the addition of the carbohydrate but prior to spray drying.
The nutritional powders comprise spray dried HMB and other nutrients. These and other exemplary features of the nutritional powders, including methods of making such powders, as well as some of the many optional variations and additions thereof, are described in detail hereafter.
The term “HMB” as used herein, unless otherwise specified, refers to beta-hydroxy-beta-methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid) and sources thereof. All weights, percentages, and concentrations as used herein to characterize HMB are based on the weight of HMB, except that all weights, percentages, and concentrations as used herein to characterize calcium HMB are based on the weight of calcium HMB monohydrate, unless otherwise specified.
The term “nutritional powder” as used herein, unless otherwise specified, refers to nutritional powders comprising HMB and at least one of protein, carbohydrate, and fat, which are reconstitutable with an aqueous liquid, and which are suitable for oral administration to a human.
The terms “fat” and “oil” as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals.
All percentages, parts and ratios as used herein, are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.
All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
The various embodiments of the nutritional powders of the present disclosure may also be substantially free of any optional or selected essential ingredient or feature described herein, provided that the remaining nutritional powder still contains all of the required ingredients or features as described herein. In this context, and unless otherwise specified, the term “substantially free” means that the selected nutritional powder contains less than a functional amount of the optional ingredient, typically less than about 0.5%, including less than about 0.1%, and also including zero percent, by weight of such optional or selected essential ingredient.
The nutritional powders and corresponding manufacturing methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements of the disclosure as described herein, as well as any additional or optional element described herein or otherwise useful in nutritional powder formula applications.
Product Form
The nutritional powders are typically in the form of flowable or substantially flowable particulate compositions, or at least particulate compositions that can easily be scooped and measured with a spoon or similar other device, wherein the compositions can easily be reconstituted by the intended user with a suitable aqueous liquid, typically water, to form a liquid nutritional formulation for immediate oral or enteral use. In this context, “immediate” use generally means within about 48 hours, most typically within about 24 hours, preferably right after reconstitution. In accordance with exemplary embodiments disclosed herein, the nutritional powders are produced by spray drying.
The nutritional powders may be formulated with sufficient kinds and amounts of nutrients so as to provide a sole, primary, or supplemental source of nutrition, or to provide a specialized nutritional powder for use in individuals afflicted with specific diseases or conditions. In one specific embodiment, the nutritional powder may be formulated for use with individuals for maintaining or building muscle mass.
The nutritional powders may be reconstituted with water prior to use to a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the powders are reconstituted with water to form compositions comprising from about 100 kcal to about 500 kcal per 240 ml, including from about 150 to about 350 kcal per 240 ml, and also including from about 200 kcal to about 320 kcal per 240 ml. The amount of calcium HMB in the reconstituted liquids most typically ranges from about 0.4 g per 240 ml to about 3 g per 240 ml, including from about 0.75 g per 240 ml to about 2 g per 240 ml, and including about 1.5 g per 240 ml.
Although the serving size for the reconstituted nutritional liquid can vary depending upon a number of variables, a typical serving size ranges from about 100 ml to about 300 ml, including from about 150 ml to about 250 ml, and including from about 190 ml to about 240 ml.
Macronutrients
The nutritional powders comprise at least one of protein, carbohydrate, and fat. In accordance with certain embodiments, the nutritional powders comprise protein. In accordance with the preceding and other embodiments, at least a portion of the protein is soluble protein. In addition, in accordance with certain embodiments, the nutritional powders disclosed herein include protein and at least one of carbohydrate and fat. Generally, any source of protein, carbohydrate, and fat that is known or otherwise suitable for use in nutritional products may be suitable for use herein, provided that such macronutrients are also compatible with the essential elements and other desired properties of the nutritional powders as defined herein.
Although total concentrations or amounts of the protein, carbohydrate, and fat may vary depending upon the nutritional needs of the intended user, such concentrations or amounts most typically fall within one of the following embodied ranges, inclusive of any other essential protein, carbohydrate, and fat ingredients as described herein.
Protein concentrations may range from 0 to about 90%, including from about 5% to about 75%, including from about 8% to about 50%, and also including from about 12% to about 30%, by weight of the nutritional powder.
Carbohydrate concentrations may range from 0 to about 99%, including from about 20% to about 90%, including from about 30% to about 80%, and also including from about 40% to about 70%, by weight of the nutritional powder.
Fat concentrations in the nutritional powders may range from 0 to about 99%, including from about 5% to about 75%, including from about 10% to about 35%, and also including from about 15% to about 20%, by weight of the nutritional powder.
The range or level of protein, carbohydrate, and fat in the nutritional powders may also be characterized in addition to or in the alternative as a percentage of total calories in the nutritional powder as set forth in the following table.
Embodiment B | Embodiment C | ||
Embodiment A | (% of Total | (% of Total | |
Nutrient | (% of Total Calories) | Calories) | Calories) |
Protein | 1-98 | 5-70 | 15-35 |
Carbohydrate | 1-98 | 10-75 | 30-50 |
Fat | 1-98 | 20-85 | 35-55 |
Non-limiting examples of suitable protein or sources thereof for use in the nutritional powders include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, which may be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy, potato, pea) or combinations thereof. Non-limiting examples of such proteins include whey protein concentrates, whey protein isolates, whey protein hydrolysates, acid caseins, sodium caseinates, calcium caseinates, potassium caseinates, casein hydrolysates, milk protein concentrates, milk protein isolates, milk protein hydrolysates, nonfat dry milk, whole cow's milk, partially or completely defatted milk, condensed skim milk, soy protein concentrates, soy protein isolates, soy protein hydrolysates, pea protein concentrates, pea protein isolates, pea protein hydrolysates, collagen proteins, potato proteins, collagen proteins, and combinations thereof.
Non-limiting examples of suitable carbohydrates or sources thereof for use in the nutritional powders include maltodextrin, hydrolyzed or modified starch or cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrates, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), and combinations thereof.
Non-limiting examples of suitable fats or sources thereof for use in the nutritional powders include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, and combinations thereof.
Soluble Protein
In accordance with certain embodiments disclosed herein, at least a portion of the protein used to formulate the nutritional powders is soluble protein. The term “soluble protein” as used herein, unless otherwise specified, refers to those proteins having a solubility of at least about 90% as measured in accordance with a Protein Solubility Measurement Test that includes the following steps: (1) suspend the protein at 2.00% (w/w) in water; (2) stir vigorously for one hour at 20° C. to form a suspension; (3) remove an aliquot of the suspension, and determine protein concentration as total protein; (4) centrifuge the suspension at 31,000 rpm and at 20° C. for one hour; (5) determine the protein concentration in the supernatant (the soluble protein); and (6) express the soluble protein as a percentage of the total protein.
The soluble protein may represent from about 50% to 100%, including from 55% to 100%, including from about 60% to about 100%, including from about 40% to about 85%, including from about 60% to about 80%, and also including from about 65% to about 75%, by weight of the total protein in the nutritional powder. The concentration of soluble protein may range from at least about 0.5%, including from about 0.5% to about 26%, including about 1% to about 26%, and also including from about 2% to about 15%, also including from about 3% to about 10%, and also including from about 4% to about 8%, by weight of the nutritional powder.
The amount of soluble protein included in the nutritional powder may also be characterized as a weight ratio of soluble protein to calcium HMB, where the nutritional powder includes a weight ratio of soluble protein to calcium HMB of at least about 3, including from about 3 to about 12, including from about 4 to about 12, also including from about 6.1 to about 12, also including from about 7 to about 11, and also including from about 8 to about 10.
Any soluble protein source is suitable for use herein provided that it meets the solubility requirement as defined herein. Non-limiting examples of suitable soluble protein includes sodium caseinate (>95% solubility as determined by the Protein Solubility Measurement Test), whey protein concentrate (>90% solubility as determined by the Protein Solubility Measurement Test), calcium caseinate (>95% solubility as determined by the Protein Solubility Measurement Test), milk protein isolate (>95% solubility as determined by the Protein Solubility Measurement Test), and combinations thereof. In certain embodiments, non-soluble proteins may also be included in the nutritional powders provided that the soluble protein component is represented in accordance with the requirements as set forth herein.
Soluble protein suitable for use herein may also be characterized by the content of phosphoserine in the protein, wherein the soluble proteins in this context are defined as those proteins having at least about 100 mmoles, including from about 150 to about 400 mmoles, including from about 200 to about 350 mmoles, and also including from about 250 to about 350 mmoles, of phosphoserine per kilogram of protein.
When the soluble protein is defined in terms of phosphoserine content, it has been found that the weight ratio of the soluble protein (with the defined phosphoserine content) to the calcium HMB may be at least about 3:1, including at least about 5:1, and also including at least about 7:1, and also including from about 9:1 to about 30:1. In this context, the proteins having the requisite content of phosphoserine are most typically in the form of monovalent caseinate salts such as sodium caseinate, calcium caseinate, potassium caseinate, and combinations thereof.
In one embodiment, the soluble protein may also be characterized by a mole ratio of monovalent caseinate phosphoserine to calcium HMB monohydrate of least about 0.2, including from about 0.2 to about 2, and also including from about 0.25 to about 1.7.
It should be understood, however, that any phosphoserine-containing protein may be suitable for use herein provided that it has the requisite phosphoserine content and that the phosphoserine used in calculating the ratios are not bound, complexed, or otherwise attached to a polyvalent cation such as calcium or magnesium.
It should also be noted that alternative definitions as described herein for soluble proteins may include proteins that have little or no phosphoserine content, so that the soluble protein fraction of the compositions may include soluble protein with or without phosphoserine. The soluble protein for use herein may therefore be defined by any one or more of the soluble protein characterizations, separately or in combination.
The phosphoserine moieties within the protein may therefore be available for binding with the calcium released from the calcium HMB so that the above ratios of soluble protein to calcium HMB are the ratio of protein with phosphoserine moities that are unbound, unattached, or otherwise available to bind soluble calcium from the calcium HMB during formulation. It could be, for example, that a mixture of calcium caseinate and sodium caseinate are used in the composition, but the ratio of proteins defined by a phosphoserine content to calcium HMB is calculated based on the protein fraction from the sodium caseinate and additionally any protein from the calcium caseinate fraction that is not bound to calcium.
HMB
The HMB component of the nutritional powders may be obtained from any HMB source suitable for use in a nutritional product. Such sources include HMB as a free acid, a salt, an anhydrous or hydrated salt, an ester, a lactone, or other forms that otherwise provide a bioavailable form of HMB for the nutritional powder.
Non-limiting examples of suitable HMB sources include HMB salts, hydrated or anhydrous, of sodium, potassium, magnesium, chromium, calcium, or other non-toxic salt forms. Calcium HMB is used in accordance with certain embodiments disclosed herein, and is most typically formulated or otherwise obtained as calcium HMB monohydrate, a commercially available source of which is available from Technical Sourcing International (TSI) of Salt Lake City, Utah USA.
The total concentration of HMB in the nutritional powders may range up to about 10%, including from about 0.1% to about 10%, including from about 0.1% to about 8%, and also including from about 0.2% to about 5.0%, and also including from about 0.3% to about 3%, and also including from about 0.4% to about 1.5%, by weight of the nutritional powder. Such concentrations may represent the concentration of HMB or the HMB source for use in the composition. In accordance with certain embodiments, when the HMB source is calcium HMB, the total concentration of calcium HMB (e.g., calcium HMB monohydrate) in the nutritional powders may range up to about 10%, including from about 0.1% to about 10%, including from about 0.1% to about 8%, and also including from about 0.2% to about 5.0%, and also including from about 0.3% to about 3%, and also including from about 0.4% to about 1.5%, by weight of the nutritional powder.
All or a portion of the HMB, including but not limited to calcium HMB, used in the preparation of the final nutritional powder is in the form of spray dried calcium HMB, as described herein.
Chelating Agents
In accordance with certain embodiments, the nutritional powders disclosed herein include at least one chelating agent. As discussed above, the presence of calcium HMB in the formulation used to produce the nutritional powder can adversely affect the manufacture and production of spray dried powders. In particular, the presence of the calcium HMB in the formulation will tend to cause protein present in the formulation to aggregate or form sediment, as a result of disassociated calcium from the calcium HMB interacting with the protein. The aggregation and sedimentation of the protein prompts the need for more frequent cleaning and maintenance of the spray drying equipment, as the aggregation and sedimentation may cause the equipment to operate less efficiently, and in some instances clog. The presence of the chelating agent in the formulations of the nutritional powders disclosed herein can reduce or minimize the aforementioned physical stability issues caused by the presence of the calcium HMB in the nutritional powders containing protein. The chelating agents are effective to minimize or reduce the aggregation and sedimentation during the production of the spray dried nutritional powder when the chelating agent and the calcium HMB are given time to chelate prior to the introduction of protein to the formulation. Accordingly, as discussed in greater detail below, the chelating agent and the calcium HMB are introduced into the slurry used to prepare the spray dried nutritional powder and held for at least 10 minutes prior to introduction of the protein into such slurry.
Nonlimiting examples of suitable chelating agents for use in the nutritional powders disclosed herein include citrates and phosphates. Examples of soluble citrates include, but are not limited to, alkali metal salts of citrates, such as potassium citrate, and sodium citrate. Examples of soluble phosphates include, but are not limited to, alkali metal salts of phosphates, such as dipotassium phosphate, disodium phosphate (commonly available in anhydrous form), and the like, and alkali earth metal salts of phosphates, such as tricalcium phosphate.
Soluble Calcium Binding Capacity
The amount of chelating agents used to reduce or minimize the production issues associated with the calcium HMB, may be characterized in terms of the weight ratio of soluble calcium binding capacity (SCBC) to total soluble calcium in the nutritional powder. This ratio is determined according to the following formulas I and II:
Ratio=SCBC/[soluble calcium] (I),
and
SCBC=(0.32×[soluble citrate]+0.63[soluble phosphate]+0.013×[soluble protein]) (II),
Ratio=SCBC/[soluble calcium] (I),
and
SCBC=(0.32×[soluble citrate]+0.63[soluble phosphate]+0.013×[soluble protein]) (II),
-
- where [soluble calcium], [soluble citrate], [soluble phosphate], and [soluble protein] represent the concentration (w/w) of each respective component in the nutritional powder.
The weight ratio of SCBC to the concentration of total soluble calcium can be adjusted to minimize the concentration of unbound (disassociated) calcium that is present in the slurry that is used during the spray drying of the powder, or to minimize the weight ratio of such unbound (disassociated) calcium to HMB in the slurry. This adjustment improves the slurry's physical stability, and consequently minimizes or reduces the production issues associated with spray drying nutritional product comprising calcium HMB.
The ratio of the soluble calcium binding capacity, as defined above, to total soluble calcium of the nutritional emulsions is a weight ratio of at least about 2.3, including from about 2.3 to about 12.0, also including from about 3.0 to about 8.0, and also including from about 4.0 to about 6.5.
The nutritional powders of the present disclosure comprise soluble calcium as a desirable ingredient to facilitate developing or maintaining of healthy muscle in targeted individuals. In this context, the term “soluble calcium” refers to the equivalents of ionized or supernatant calcium in the slurry used to prepare the spray dried powder as measured at 20° C. At least a portion of the soluble calcium is provided by calcium HMB as described herein. Any other calcium source, however, may be used provided that such other source is compatible with the essential other ingredients of the nutritional powders disclosed herein as well as compatible with the requirements set forth by the ratio of SCBC to total calcium as described above.
The calcium in the nutritional powders may also be characterized by a ratio (on an equivalents basis) of soluble citrate to soluble calcium of not more than 5, including not more than 4, also including not more than 3, and also including from about 0.8 to about 3. In this context, the terms “soluble citrate” refers to the equivalents of citrate cations, respectively, present in supernatants of the nutritional slurry as measured at 20° C.
In accordance with certain embodiments, the weight ratio of calcium HMB to the soluble calcium ranges from about 6:1 to about 15:1, including from about 6:1 to about 12:1, also including from about 6:1 to about 10:1, and also including from about 6:1 to about 8:1.
Vitamin D
The nutritional powders may further comprise vitamin D to help maintain healthy muscle in the targeted user. Vitamin D forms include Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol) or other forms suitable for use in a nutritional product.
The amount of Vitamin D in the nutritional powder typically ranges up to about 1000 IU, including from about 10 IU to about 600 IU, and also including from about 50 IU to about 400 IU per serving size as described herein.
Optional Ingredients
The nutritional powders may further comprise other optional ingredients that may modify the physical, chemical, hedonic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population. Many such optional ingredients are known or otherwise suitable for use in other nutritional products and may also be used in the nutritional powders described herein, provided that such optional ingredients are suitable for oral administration and are compatible with the essential ingredients in the nutritional powders.
Non-limiting examples of such optional ingredients include preservatives, antioxidants, emulsifying agents, buffers, pharmaceutical actives, additional nutrients as described herein, colorants, flavors, thickening agents, stabilizers, and masking agents, and combinations thereof.
The nutritional powders may further comprise vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B12, carotenoids, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts, and derivatives thereof, and combinations thereof.
The nutritional powders may further comprise minerals, non-limiting examples of which include phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, selenium, chloride, and combinations thereof.
Method of Use
The nutritional powders are reconstituted with water or other suitable liquid to provide a nutritional liquid. Such liquids from the powders described herein are useful in methods of providing supplemental, primary, or sole sources of nutrition, or in methods of providing individuals one or more benefits as described herein. In certain embodiments, the liquids may be administered orally as needed to provide the desired level of nutrition, most typically in the form of one to two servings daily, in one or more divided doses daily. For example, serving sizes typically ranging from about 100 ml to about 300 ml, including from about 150 ml to about 250 ml, and including from about 190 ml to about 240 ml, wherein each serving contains from about 0.4 g to about 3.0 g, including from about 0.75 g to about 2.0 g, and including about 1.5 g, of calcium HMB per serving.
Such methods are further directed to providing individuals upon administration of such products, most typically after daily use over an extended period of time of from about 1 month to about 6 months, including from about 1 month to about 3 months, one or more of 1) supporting maintenance of lean body mass, 2) supporting of strength, muscle strength or both, 3) decreasing protein breakdown and damage of muscle cells, and 4) helping with muscle recovery following exercise or other trauma, and 5) reducing muscle protein breakdown following exercise.
Such methods are also helpful to achieve one or more of 1) maintaining and supporting lean body mass in elderly with sarcopenia, 2) providing nutrition to support an active and independent lifestyle in individuals, especially in the elderly, 3) supporting recovery of muscle strength, 4) helping rebuild muscle and regain strength, and 5) improving strength, including muscle strength, and mobility.
Methods of Manufacture
The nutritional powders may be prepared by any collection of known or otherwise effective techniques, suitable for making and formulating a nutritional powder provided that the techniques include or are modified to include a spray drying step to provide the powder with the requisite spray dried HMB ingredient.
The spray drying step may likewise include any spray drying technique that is known for or otherwise suitable for use in the production of nutritional powders. Many different spray drying methods and techniques are known for use in the nutrition field, all of which may be suitable for use in the manufacture of the nutritional powders herein.
One method of preparing the nutritional powder comprises forming an aqueous slurry or liquid comprising HMB and at least one of protein, carbohydrate, and fat, and then spray drying the slurry or liquid to produce a spray dried nutritional powder comprising spray dried HMB and having improved sensory properties. The method may further comprise the step of spray drying, dry mixing (also known as dry blending), or otherwise adding additional nutritional ingredients, including any one or more of the ingredients described herein, to the spray dried nutritional powder.
In some embodiments, the methods of manufacture are formulated with calcium HMB, which is most typically formulated as calcium HMB monohydrate, as the HMB source for use in the methods.
In accordance with certain embodiments, when the nutritional powders for spray drying are formulated with calcium HMB, the nutritional powders are formulated with at least one chelating agent in the following manner so as to minimize or avoid the aggregation and sedimentation issues associated with the use of calcium HMB. Firstly, the chelating agents are admixed into an aqueous slurry or liquid. The calcium HMB is then admixed to the aqueous slurry or liquid containing the chelating agents. The aqueous slurry or liquid containing the chelating agents and the calcium HMB are then held for at least 10 minutes under agitation, so to allow the disassociated or unbound calcium from the calcium HMB to chelate with the chelating agents in the slurry or liquid. Following the hold time, the protein, of which at least a portion is soluble protein as discussed herein, is admixed into the aqueous slurry or liquid. In accordance with certain of the preceding embodiments, when the nutritional powder formulation contains carbohydrates, the at least a portion of the carbohydrates is added before the protein is added to the slurry. Any other portion of carbohydrates may be dry mixed into the nutritional powder following spray drying. In accordance with certain of the preceding embodiments, when fat is present in the formulation of the nutritional powder, the fat is added after the protein and any carbohydrate are added, but before spray drying. The following paragraphs outline an exemplary, more detailed description of the formulation of slurries which may be used in the preparation of the exemplary spray dried nutritional powders disclosed herein.
In one suitable method of manufacturing the nutritional powder, at least three separate slurries are prepared, including a protein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MN) slurry, and a protein-in-water (PIW) slurry. The PIF slurry is formed by heating and mixing the selected oils (e.g., canola oil, corn oil) to a specified temperature and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate) with continued heat and agitation. The CHO-MN slurry is formed by adding with heated agitation to water: minerals (e.g., potassium citrate, dipotassium phosphate, sodium citrate), trace and ultra trace minerals (TM/UTM premix), thickening or suspending agents (e.g., gellan, carrageenan), and calcium HMB and any additional other HMB source. The heated agitation occurs at a specified temperature range. The resulting CHO-MIN slurry is held for 10 minutes with continued heat and agitation before adding any additional minerals (e.g., potassium chloride, magnesium carbonate, potassium iodide) and any carbohydrates (e.g., frucotooligosaccharide, sucrose, corn syrup). The third, PIW slurry is then formed by mixing with heat, at a specified temperature range, and agitation the remaining protein (e.g., sodium caseinate, soy protein concentrate) into water.
The resultant slurries are then blended together with heated agitation, at a specified temperature range, and the pH adjusted to the desired range, typically from 6.6-7.0, after which the composition is subjected to high-temperature short-time (HTST) processing during which the composition is heat treated as is known in the art, emulsified and homogenized. Water soluble vitamins and ascorbic acid are added, the pH is again adjusted to the desired range if necessary, flavors are added, and water is added to achieve the desired total solid level. The resultant slurry is then subjected to spray drying to form the nutritional powder.
In accordance with one or more of the methods of manufacture disclosed herein, a method is directed to the preparation of a nutritional powder comprising spray dried HMB. The method includes preparing an aqueous slurry by admixing at least one chelating agent followed by soluble calcium to water. At least a portion of the soluble calcium is calcium HMB, and the at least one chelating agent is selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof. The method also includes holding the aqueous slurry under agitation for at least 10 minutes; admixing protein to the aqueous slurry, where at least a portion of the protein is soluble protein; and spray drying the aqueous slurry to produce the nutritional powder. The nutritional powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1. In accordance with the preceding and other exemplary embodiments, the method further comprises admixing carbohydrate to the aqueous slurry prior the addition of the protein. Additionally, in accordance with the preceding and other embodiments, the method further comprises admixing fat into the aqueous slurry after the addition of the protein and any carbohydrate but prior to spray drying.
In accordance with some of the exemplary methods of manufacture disclosed herein, all of the HMB in the nutritional powder is spray dried as described herein, including from about 50% to about 100%, by weight of the nutritional powder is spray dried as well. In certain embodiments therefore, most or all of the ingredients in the nutritional powder, including all of the HMB in the powder, are spray dried together to form a spray dried nutritional powder wherein 100% of the HMB is therefore spray dried HMB.
Also in accordance with some of the exemplary methods of manufacture disclosed herein, a portion of the HMB in the nutritional powder may be spray dried with some or all of at least one of the protein, carbohydrate, and/or the fat in the nutritional powder, including from about 20% to about 90%, also including from about 40% to about 90%, and also including from about 50% to about 80%, by weight of the total HMB as spray dried HMB. In such nutritional powders, a portion of the HMB may be non-spray dried and thus represent from about 10% to about 80%, including from about 10% to about 60%, and also including from about 20% to about 50%, by weight of the total HMB in the nutritional powder.
The nutritional powders are preferably spray dried to a moisture content of less than about 3.0%, most typically from about 1.0% to about 2.8%, by weight of the finished powder.
The following examples illustrate specific embodiments and/or features of the nutritional powders comprising spray dried HMB. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present disclosure, as many variations thereof are possible without departing from the spirit and scope of the general inventive concepts. All exemplified amounts are weight percentages based upon the total weight of the composition, unless otherwise specified.
The exemplified compositions are nutritional powders prepared in accordance with the manufacturing methods described herein, such that each exemplified nutritional powder comprising spray dried HMB has minimal or no protein aggregation or sedimentation issues associated with the calcium HMB, along with minimal or no off odors when packaged in sealed containers, and then a portion of which is later removed and reconstituted with water to the desired caloric density to form a nutritional liquid containing 1.5 g of calcium HMB monohydrate per 240 ml of reconstituted liquid. The 240 ml liquid represents a single serving suitable for oral administration within 48 hours following such constitution.
In general, each of the exemplified compositions can be manufactured by 1) preparing a first liquid slurry (CHO/MIN) comprising adding chelating agents, followed by calcium HMB monohydrate and any minerals to water, then after a 10 minute hold time, adding the carbohydrates, and, 2) preparing a second liquid slurry comprising oils, stabilizers, oil soluble vitamins, and protein (PIF), 3) preparing a third liquid slurry comprising protein an water (PIW), 4) blending the first and second slurries together, and then blending the resulting slurry with the third slurry, 5) subjecting the resulting blend to homogenization and heat treatment, 6) standardizing the resulting homogenized blend with vitamins, flavors, trace and ultra trace minerals, and other heat sensitive ingredients, and then 7) spray drying the standardized blend to form a spray dried nutritional powder. The spray dried powder is then package and hermetically sealed in appropriate containers suitable for long term storage prior to use, during which the product may be opened and product reconstituted to form a nutritional liquid and administered in accordance with the methods described herein.
Examples 1-4 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kilogram per 1000 kilogram batch of product, unless otherwise specified.
Ingredient | Example 1 | Example 2 | Example 3 | Example 4 |
Whey Protein | 282.051 | 293.892 | 289.892 | 284.892 |
Concentrate | ||||
Calcium Caseinate | 192.308 | 192.308 | 192.308 | 192.308 |
Maltodextrin | 165.416 | 165.416 | 165.416 | 165.416 |
Milk Protein Isolate | 138.782 | 138.782 | 138.782 | 138.782 |
Cocoa | 76.932 | 76.932 | 76.932 | 76.932 |
Sunflower Oil Creamer | 21.474 | 21.474 | 21.474 | 21.474 |
Oil Preblend | 19.231 | 19.231 | 19.231 | 19.231 |
Chocolate Cream | 15.256 | 15.256 | 15.256 | 15.256 |
Calcium HMB | 13.157 | 1.316 | 5.316 | 10.316 |
Monohydrate | ||||
Oat Fiber | 10.897 | 10.897 | 10.897 | 10.897 |
Tricalcium Phosphate | 8.526 | 8.526 | 8.526 | 8.526 |
Vitamin Mineral | 8.462 | 8.462 | 8.462 | 8.462 |
Preblend | ||||
Dipotassium Phosphate | 8.333 | 8.333 | 8.333 | 8.333 |
Rich Dark Chocolate | 7.051 | 7.051 | 7.051 | 7.051 |
Carrageenan | 6.474 | 6.474 | 6.474 | 6.474 |
Potassium Chloride | 5.128 | 5.128 | 5.128 | 5.128 |
Salt | 3.205 | 3.205 | 3.205 | 3.205 |
Xanthan Gum | 3.205 | 3.205 | 3.205 | 3.205 |
Choline Bitartrate 41% | 2.782 | 2.782 | 2.782 | 2.782 |
Choline | ||||
Acesulfame K | 2.718 | 2.718 | 2.718 | 2.718 |
Vanilla | 1.923 | 1.923 | 1.923 | 1.923 |
Disodium Phosphate | 1.667 | 1.667 | 1.667 | 1.667 |
Anhydrous | ||||
Whey Protein Isolate | 1.282 | 1.282 | 1.282 | 1.282 |
Beta Carotene 1% | 1.128 | 1.128 | 1.128 | 1.128 |
Sucralose | 692.3 g | 692.3 | 692.3 | 692.3 |
Potassium Citrate 38% K | 641.0 g | 641.0 | 641.0 | 641.0 |
Alpha ketoglutaric Acid | 321.0 g | 321.0 | 321.0 | 321.0 |
Egg Albumin Powder | 321.0 g | 321.0 | 321.0 | 321.0 |
L-Glutamine | 321.0 g | 321.0 | 321.0 | 321.0 |
Taurine | 321.0 g | 321.0 | 321.0 | 321.0 |
Examples 5-8 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
Ingredient | Example 5 | Example 6 | Example 7 | Example 8 |
Whey Protein | 280.051 | 272.051 | 262.051 | 232.051 |
Concentrate | ||||
Calcium Caseinate | 192.308 | 192.308 | 192.308 | 192.308 |
Maltodextrin | 165.416 | 165.416 | 165.416 | 165.416 |
Milk Protein Isolate | 138.782 | 138.782 | 138.782 | 138.782 |
Cocoa | 76.932 | 76.932 | 76.932 | 76.932 |
Sunflower Oil Creamer | 21.474 | 21.474 | 21.474 | 21.474 |
Oil Preblend | 19.231 | 19.231 | 19.231 | 19.231 |
Chocolate Cream | 15.256 | 15.256 | 15.256 | 15.256 |
Calcium HMB | 15.157 | 25.157 | 35.157 | 50.157 |
Monohydrate | ||||
Oat Fiber | 10.897 | 10.897 | 10.897 | 10.897 |
Tricalcium Phosphate | 8.526 | 8.526 | 8.526 | 8.526 |
Vitamin Mineral | 8.462 | 8.462 | 8.462 | 8.462 |
Preblend | ||||
Dipotassium Phosphate | 8.333 | 7.051 | 7.051 | 7.051 |
Rich Dark Chocolate | 7.051 | 7.051 | 7.051 | 7.051 |
Carrageenan | 6.474 | 6.474 | 6.474 | 6.474 |
Potassium Chloride | 5.128 | 5.128 | 5.128 | 5.128 |
Salt | 3.205 | 3.205 | 3.205 | 3.205 |
Xanthan Gum | 3.205 | 3.205 | 3.205 | 3.205 |
Choline Bitartrate 41% | 2.782 | 2.782 | 2.782 | 2.782 |
Choline | ||||
Acesulfame K | 2.718 | 2.718 | 2.718 | 2.718 |
Vanilla | 1.923 | 1.923 | 1.923 | 1.923 |
Disodium Phosphate | 1.667 | 1.667 | 1.667 | 1.667 |
Anhydrous | ||||
Whey Protein Isolate | 1.282 | 1.282 | 1.282 | 1.282 |
Beta Carotene 1% | 1.128 | 1.128 | 1.128 | 1.128 |
Sucralose | 692.3 g | 692.3 g | 692.3 g | 692.3 g |
Potassium Citrate 38% K | 641.0 g | 641.0 g | 641.0 g | 641.0 g |
Alpha ketoglutaric Acid | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Egg Albumin Powder | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
L-Glutamine | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Taurine | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Examples 9-12 illustrate nutritional powders of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
Example | Example | Example | ||
Ingredient | Example 9 | 10 | 11 | 12 |
Whey Protein | 235.051 | 230.051 | 225.051 | 216.051 |
Concentrate | ||||
Calcium Caseinate | 192.308 | 192.308 | 192.308 | 192.308 |
Maltodextrin | 165.416 | 165.416 | 165.416 | 165.416 |
Milk Protein Isolate | 138.782 | 138.782 | 138.782 | 138.782 |
Dutch Cocoa | 76.932 | 76.932 | 76.932 | 76.932 |
Sunflower Oil Creamer | 21.474 | 21.474 | 21.474 | 21.474 |
Oil Preblend | 19.231 | 19.231 | 19.231 | 19.231 |
Chocolate Cream | 15.256 | 15.256 | 15.256 | 15.256 |
Calcium HMB | 60.157 | 65.157 | 70.157 | 79.157 |
Monohydrate | ||||
Oat Fiber | 10.897 | 10.897 | 10.897 | 10.897 |
Tricalcium Phosphate | 8.526 | 8.526 | 8.526 | 8.526 |
Vitamin Mineral | 8.462 | 8.462 | 8.462 | 8.462 |
Preblend | ||||
Dipotassium Phosphate | 8.333 | 8.333 | 8.333 | 8.333 |
Rich Dark Chocolate | 7.051 | 7.051 | 7.051 | 7.051 |
Carrageenan | 6.474 | 6.474 | 6.474 | 6.474 |
Potassium Chloride | 5.128 | 5.128 | 5.128 | 5.128 |
Salt | 3.205 | 3.205 | 3.205 | 3.205 |
Xanthan Gum | 3.205 | 3.205 | 3.205 | 3.205 |
Choline Bitartrate 41% | 2.782 | 2.782 | 2.782 | 2.782 |
Choline | ||||
Acesulfame K | 2.718 | 2.718 | 2.718 | 2.718 |
Vanilla | 1.923 | 1.923 | 1.923 | 1.923 |
Disodium Phosphate | 1.667 | 1.667 | 1.667 | 1.667 |
Anhydrous | ||||
Whey Protein Isolate | 1.282 | 1.282 | 1.282 | 1.282 |
Beta Carotene 1% | 1.128 | 1.128 | 1.128 | 1.128 |
Sucralose | 692.3 g | 692.3 g | 692.3 g | 692.3 g |
Potassium Citrate 38% K | 641.0 g | 641.0 g | 641.0 g | 641.0 g |
Alpha ketoglutaric Acid | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Egg Albumin Powder | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
L-Glutamine | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Taurine | 321.0 g | 321.0 g | 321.0 g | 321.0 g |
Claims (7)
1. A method of preparing a nutritional powder comprising spray dried calcium beta-hydroxy-beta-methylbutyrate (HIVIB), the method comprising:
preparing an aqueous slurry by admixing at least one chelating agent followed by soluble calcium to water, wherein at least a portion of the soluble calcium is calcium HMB and wherein the at least one chelating agent is selected from the group consisting of a soluble citrate, a soluble phosphate, and combinations thereof;
holding the aqueous slurry under agitation for at least 10 minutes;
admixing protein to the aqueous slurry containing the chelating agent and the soluble calcium, wherein at least a portion of the protein is soluble protein; and
spray drying the aqueous slurry to produce the nutritional powder,
wherein the powder has a weight ratio of soluble calcium binding capacity to total soluble calcium from about 2.3:1 to about 12:1.
2. The method of claim 1 , further comprising:
admixing carbohydrate to the aqueous slurry prior the addition of the protein.
3. The method of claim 2 , further comprising:
admixing fat into the aqueous slurry after the addition of the carbohydrate but prior to spray drying.
4. The method of claim 2 , further comprising dryblending additional carbohydrate into the nutritional powder following the spray drying.
5. The method of claim 1 , wherein the powder comprises from about 0.1% to about 8% by weight of calcium HMB.
6. The method of claim 5 , wherein the powder comprises from about 12% to about 30% protein, from about 30% to about 80% carbohydrate, and from about 10% to about 35% fat, all by weight of the nutritional powder.
7. The method of claim 1 , wherein the at least one chelating agent is selected from the group consisting of tricalcium phosphate, dipotassium phosphate, disodium phosphate, and potassium citrate.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/043,470 US9693577B2 (en) | 2010-01-29 | 2013-10-01 | Method of preparing a nutritional powder comprising spray dried HMB |
US15/638,487 US20170295836A1 (en) | 2010-01-29 | 2017-06-30 | Nutritional powders comprising spray dried hmb |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29963210P | 2010-01-29 | 2010-01-29 | |
US13/016,041 US20110256299A1 (en) | 2010-01-29 | 2011-01-28 | Nutritional Powders Comprising Spray Dried HMB |
US14/043,470 US9693577B2 (en) | 2010-01-29 | 2013-10-01 | Method of preparing a nutritional powder comprising spray dried HMB |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/016,041 Continuation-In-Part US20110256299A1 (en) | 2010-01-29 | 2011-01-28 | Nutritional Powders Comprising Spray Dried HMB |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/638,487 Continuation US20170295836A1 (en) | 2010-01-29 | 2017-06-30 | Nutritional powders comprising spray dried hmb |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140030420A1 US20140030420A1 (en) | 2014-01-30 |
US9693577B2 true US9693577B2 (en) | 2017-07-04 |
Family
ID=49995141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/043,470 Active 2033-01-09 US9693577B2 (en) | 2010-01-29 | 2013-10-01 | Method of preparing a nutritional powder comprising spray dried HMB |
US15/638,487 Abandoned US20170295836A1 (en) | 2010-01-29 | 2017-06-30 | Nutritional powders comprising spray dried hmb |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/638,487 Abandoned US20170295836A1 (en) | 2010-01-29 | 2017-06-30 | Nutritional powders comprising spray dried hmb |
Country Status (1)
Country | Link |
---|---|
US (2) | US9693577B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2932204A1 (en) * | 2015-06-25 | 2016-12-25 | Alaya Care Inc. | Method for predicting adverse events for home healthcare of remotely monitored patients |
WO2022177516A1 (en) * | 2021-02-17 | 2022-08-25 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Nutritional powder compositions for promoting wound healing |
Citations (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105763A (en) | 1960-03-22 | 1963-10-01 | Beatrice Foods Co | Concentrated milk |
US3408210A (en) | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
US3542560A (en) | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
US4104290A (en) | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
US4259358A (en) | 1974-02-14 | 1981-03-31 | Agricultural Production And Vegetable Products, Ltd. | Preparation of food products |
EP0036663A1 (en) | 1980-03-24 | 1981-09-30 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Oxiranebutanoic acid derivatives, their preparation and use, and medicaments containing them |
US4742081A (en) | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
EP0367724A1 (en) | 1988-10-31 | 1990-05-09 | Sandoz Nutrition Ltd. | Improvements in or relating to organic compounds |
EP0385859A1 (en) | 1989-03-01 | 1990-09-05 | Roberto Luis Dr. Ceriani | Composition for enhancing cancer therapy by administration of unsaturated fatty acids |
US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
US5000975A (en) | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US5087472A (en) | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
US5167957A (en) | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
US5171442A (en) | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
JPH05503508A (en) | 1989-11-22 | 1993-06-10 | バーバル、エイドリアン | How to reduce blood cholesterol using arginine |
US5219735A (en) | 1980-02-01 | 1993-06-15 | Institut National De La Recherche Agronomique | Non-phosphorylated peptides from casein-based material |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
WO1994006417A1 (en) | 1992-09-16 | 1994-03-31 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
US5374657A (en) | 1991-01-24 | 1994-12-20 | Martek Corporation | Microbial oil mixtures and uses thereof |
US5431928A (en) | 1991-03-18 | 1995-07-11 | Meiji Seika Kaisha, Ltd. | Feed for swine and method of breeding swine using the same |
US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
US5492938A (en) | 1990-02-13 | 1996-02-20 | Martek Biosciences Corporation | Pharmaceutical composition and dietary supplement containing docosarexaenoic acid obtained from dinoflagellates |
EP0698078A1 (en) | 1993-05-13 | 1996-02-28 | Loders Croklaan Bv | Human milk fat replacers from interesterified blends of triglycerides |
EP0756827A2 (en) | 1995-08-03 | 1997-02-05 | B. Braun Melsungen Ag | Composition for nutrition |
US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
DE29707308U1 (en) | 1997-04-23 | 1997-06-26 | Kunz Armin | Preparation for muscle maintenance or to promote muscle building |
WO1998004253A1 (en) | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
US5726146A (en) | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US5780451A (en) | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US5834427A (en) | 1995-03-23 | 1998-11-10 | Sang Kee Han | Casein phosphopeptide, casein containing same and process for the preparation thereof |
JPH11508282A (en) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | Methods for preventing and treating cachexia and anorexia |
US5976550A (en) | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
WO1999066917A2 (en) | 1998-06-23 | 1999-12-29 | Iowa State University Research Foundation, Inc. | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
WO2000000001A2 (en) | 1999-10-15 | 2000-01-06 | Phonak Ag | Binaural synchronisation |
WO2000015174A2 (en) | 1998-09-15 | 2000-03-23 | Korea Institute Of Science And Technology | Bioflavonoid as blood glucose level lowering agent |
US6060446A (en) | 1994-04-29 | 2000-05-09 | Wake Forest University | Method and composition for treating renal disease and failure |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6096358A (en) | 1997-10-08 | 2000-08-01 | Abbott Laboratories | Method of manufacturing an aseptically sterilized package containing a liquid nutritional product |
US6099871A (en) | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
US6103764A (en) | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
US6227261B1 (en) | 1998-12-24 | 2001-05-08 | Abbott Laboratories | Method and apparatus for the addition of sterile liquid to an aseptic system |
US6248909B1 (en) | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
US20010008641A1 (en) | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
WO2001056402A2 (en) | 2000-02-01 | 2001-08-09 | Muscletech Research And Development Inc. | Alpha lipoic acid based food supplement to increase lean muscle mass and strength |
WO2001058284A1 (en) | 2000-02-10 | 2001-08-16 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
US6294206B1 (en) | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
JP2001288107A (en) | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | Reducing agent for adverse effect accompanied in cancer chemotherapy |
WO2001077271A2 (en) | 2000-04-06 | 2001-10-18 | Conlinco, Inc. | Conjugated linoleic acid compositions |
US6306908B1 (en) | 1997-02-21 | 2001-10-23 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
US6340491B1 (en) | 1996-04-11 | 2002-01-22 | Loders Croklaan B.V. | Free flowing fat compositions |
WO2002017735A2 (en) | 2000-08-29 | 2002-03-07 | Lonza Ag | Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
US20020035965A1 (en) | 2000-08-03 | 2002-03-28 | Zehava Uni | Enhancement of development of oviparous species by in ovo feeding |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6371319B2 (en) | 1997-09-22 | 2002-04-16 | Abbott Laboratories | Closure system for containers |
US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
JP2002521428A (en) | 1998-07-30 | 2002-07-16 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Use of L-carnitine and its alkanoyl derivative for the manufacture of a medicament having anticancer activity |
US6468987B1 (en) | 1994-04-01 | 2002-10-22 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
JP2003137790A (en) | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | Medicine including fructooligosaccharide including beta-2, 1 (beta 2 -> beta 1) bond-chain fructose oligomer as active ingredient |
US20030092609A1 (en) | 2000-02-23 | 2003-05-15 | Larsen Bjarne Due | Novel antiarrythmic peptides |
US20030118703A1 (en) | 2001-12-12 | 2003-06-26 | Nguyen Minhthy Le | Methods and compositions for brightening the color of thermally processed nutritionals |
WO2003053456A1 (en) | 2001-12-21 | 2003-07-03 | Phenion Gmbh & Co. Kg | Use of hyperforin or st john's wort extracts against anaphylactic states of shock and for maintaining and improving bone health |
US6596767B2 (en) | 1994-01-10 | 2003-07-22 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
US20030165604A1 (en) | 2001-02-15 | 2003-09-04 | Kazufumi Tsubaki | Products containing $g(b)-glucan |
US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
US20030203070A1 (en) | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
WO2003091214A1 (en) | 2002-04-23 | 2003-11-06 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
US20040013787A1 (en) | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
US20040048925A1 (en) | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040071825A1 (en) | 2002-10-15 | 2004-04-15 | Christopher Lockwood | Agglomerated granular protein-rich nutritional supplement |
US20040106678A1 (en) | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US6749881B2 (en) | 2001-03-26 | 2004-06-15 | Kao Corporation | Packaged emulsified beverage |
US20040122210A1 (en) | 2002-10-14 | 2004-06-24 | Lars Thim | GLP-2 compounds, formulations, and uses thereof |
WO2004064715A2 (en) | 2003-01-23 | 2004-08-05 | M N L Pharma Limited | Polyhydroxylated pyrrolizidine |
US20040202770A1 (en) | 2001-06-13 | 2004-10-14 | Cain Frederick William | Micronised fat particles |
US20040220266A1 (en) | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040237466A1 (en) | 2001-09-17 | 2004-12-02 | Holger Grossmann | Beverage bottling plant for filling bottles with a liquid beverage filling material, and a cleaning device for cleaning bottles in a beverage bottling plant |
US20040248771A1 (en) | 2001-11-01 | 2004-12-09 | Giuseppe Raggi | Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
US20040247755A1 (en) | 2001-09-21 | 2004-12-09 | Solvay Interox Gmbh | Stabilized hydrogen peroxide |
WO2005000315A1 (en) | 2003-06-27 | 2005-01-06 | Bioprojet | Combination product comprising an antagonist or inverse agonist of histamine receptor h3 and an antipsychotic or antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |
US20050106219A1 (en) | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
US20050249650A1 (en) | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
US20060024385A1 (en) | 2004-07-27 | 2006-02-02 | Pedersen Mark A | Metabolic capacity enhancing compositions and methods for use in a mammal |
JP2006136318A (en) | 2004-10-15 | 2006-06-01 | Otsuka Pharmaceut Factory Inc | Method for producing liquid food |
WO2006062424A2 (en) | 2004-11-08 | 2006-06-15 | Sgp & Sons Ab | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system |
US20060193961A1 (en) | 2005-02-25 | 2006-08-31 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
US20060204632A1 (en) | 2005-03-09 | 2006-09-14 | Bridget Barrett-Reis | Concentrated human milk fortifier liquid |
US20060286210A1 (en) | 2005-06-06 | 2006-12-21 | Nagendra Rangavajla | Low-phytate infant formulas |
US20060293220A1 (en) | 1999-12-17 | 2006-12-28 | Hannah Research Institude | Calcium phosphate nanoclusters and their applications |
EP1762147A1 (en) | 2005-09-09 | 2007-03-14 | Primalac Private Foundation | Nutritional concentrate for infants |
US20070125785A1 (en) | 2001-12-21 | 2007-06-07 | Robinson Clayton L | Closure for a Retort Processed Container Having a Peelable Seal |
WO2007066232A2 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
US20070142469A1 (en) | 2005-12-19 | 2007-06-21 | Thomas Debra L | Method of using beta-hydroxy-beta-methylbutyrate |
US7247320B2 (en) | 2001-11-26 | 2007-07-24 | Nestec S.A. | Shelf stable nutritional composition containing intact whey protein, process of manufacture and use |
WO2007098092A2 (en) | 2006-02-21 | 2007-08-30 | Nutrijoy, Inc. | Food and beverage products with improved taste impressions |
US20070219146A1 (en) | 2006-02-06 | 2007-09-20 | Sunil Bhaskaran | Synergistic Pharmaceutical And/Or Neutraceutical Flavanoid Composition For Management Of Diabetes Mellitus |
US20080031860A1 (en) | 2003-12-24 | 2008-02-07 | N.V. Nutricia | Compositions Comprising Pantothenic Acid or Derivatives Thereof and Their Use for Stimulating Appetite |
US7332178B2 (en) | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
US20080058415A1 (en) | 2003-10-22 | 2008-03-06 | Avidor Shulman | Lipid Preparation for Enhancing Mineral Absorption |
US20080119552A1 (en) | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
US20080193624A1 (en) | 2005-04-27 | 2008-08-14 | Enzymotec Ltd. | Human Milk Fat Substitutes |
US7419596B2 (en) | 2001-12-12 | 2008-09-02 | Martek Biosciences Corporation | Extraction and winterization of lipids from oilseed and microbial sources |
US20080209864A1 (en) | 2006-06-05 | 2008-09-04 | Stuart Fergusson | Process and apparatus for forming a minimal headspace pouch |
WO2008115723A1 (en) | 2007-03-19 | 2008-09-25 | Atm Metabolics Lllp | Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid |
US7435442B2 (en) | 2000-10-20 | 2008-10-14 | Nutriz N.V. | Non-dairy products derived from rice and method of making |
US20080254153A1 (en) | 2005-09-20 | 2008-10-16 | Junkuan Wang | Water Dispersible Composition and Method for Preparing Same |
US20080260923A1 (en) | 2004-09-09 | 2008-10-23 | Nestec S.A. | Nutritional Products Having Improved Quality and Methods and Systems Regarding Same |
US20080274230A1 (en) | 2003-10-14 | 2008-11-06 | Johns Paul W | Iron-Containing Human Milk Fortifier With Improved Antimicrobial Properties |
US20080305531A1 (en) | 2004-09-10 | 2008-12-11 | Verenium Corporation | Compositions and Methods for Making and Modifying Oils |
US20080317886A1 (en) | 2005-11-03 | 2008-12-25 | Sparkman Dennis R | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness |
US7498026B2 (en) | 2002-05-29 | 2009-03-03 | Danisco Us Inc., Genencor Division | Acyltransferase |
US20090087540A1 (en) | 2006-01-31 | 2009-04-02 | Nestec S.A. | Nutritional composition for low birth weight infants |
US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
US20090142425A1 (en) | 2004-07-24 | 2009-06-04 | Ralf Jager | Physiologically active composition |
JP2009155336A (en) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | Treating agent |
US20090220637A1 (en) | 2005-08-26 | 2009-09-03 | Nestec S.A. | Nutrition for obese patients |
US20090263367A1 (en) | 2008-04-18 | 2009-10-22 | Ryan Jason Foley | Composition and method for promoting internal health and external appearance |
CN101569412A (en) | 2009-06-01 | 2009-11-04 | 北京康比特体育科技股份有限公司 | Sports nutrition supplement and application thereof |
CN101574146A (en) | 2008-05-07 | 2009-11-11 | 北京康比特体育科技股份有限公司 | Sports nutritional supplement containing HMB |
WO2009143097A1 (en) | 2008-05-21 | 2009-11-26 | Stokely-Van Camp, Inc. | Milk-based recovery beverage |
US7648721B2 (en) | 2001-07-18 | 2010-01-19 | Dsm Ip Assets B.V. | Hydrolyzed milk proteins |
US20100074969A1 (en) | 2008-09-19 | 2010-03-25 | Unicity International, Inc. | Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix |
CN101703246A (en) | 2009-11-17 | 2010-05-12 | 卢惠强 | Exercise supplementation composition |
US20100179112A1 (en) | 2008-12-09 | 2010-07-15 | Metabolic Technologies, Inc. | Nutritional Intervention for Improving Muscular Function and Strength |
US7795204B2 (en) | 1999-10-18 | 2010-09-14 | Northern Innovations And Formulations Corp. | Food supplement for increasing lean mass and strength |
US7825084B2 (en) | 1996-08-12 | 2010-11-02 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
CA2784605A1 (en) | 2009-12-14 | 2011-06-23 | Olimp Laboratories Sp. Z O.O. | Isotonic beverage with chelates |
WO2011094549A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional powders comprising spray dried hmb |
WO2011094551A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Plastic packaged nutritonal liquids comprising hmb |
WO2011094544A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb and soluble protein |
WO2011094548A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
WO2011094557A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb |
US20110218244A1 (en) | 2009-08-12 | 2011-09-08 | Kneller Bruce W | CREATINE ß-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
US20110305799A1 (en) | 2010-06-10 | 2011-12-15 | Abbott Laboratories | Substantially clear nutritional liquids comprising calcium hmb and soluble protein |
WO2012088075A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
WO2012097064A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
WO2012109105A1 (en) | 2011-02-07 | 2012-08-16 | Abbott Laboratories | Nutritional products comprising beta-hydroxy-beta-methylbutyrate |
WO2012112419A1 (en) | 2011-02-17 | 2012-08-23 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
CA2737972A1 (en) | 2011-04-07 | 2012-10-07 | Abbott Laboratories | Aseptically packaged nutritional concentrate |
US20120283185A1 (en) | 1998-04-30 | 2012-11-08 | N.V. Nutricia | Food composition and method of using same |
-
2013
- 2013-10-01 US US14/043,470 patent/US9693577B2/en active Active
-
2017
- 2017-06-30 US US15/638,487 patent/US20170295836A1/en not_active Abandoned
Patent Citations (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105763A (en) | 1960-03-22 | 1963-10-01 | Beatrice Foods Co | Concentrated milk |
US3408210A (en) | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
US3542560A (en) | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
US4259358A (en) | 1974-02-14 | 1981-03-31 | Agricultural Production And Vegetable Products, Ltd. | Preparation of food products |
US4104290A (en) | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
US5219735A (en) | 1980-02-01 | 1993-06-15 | Institut National De La Recherche Agronomique | Non-phosphorylated peptides from casein-based material |
EP0036663A1 (en) | 1980-03-24 | 1981-09-30 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Oxiranebutanoic acid derivatives, their preparation and use, and medicaments containing them |
US4742081A (en) | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
EP0367724A1 (en) | 1988-10-31 | 1990-05-09 | Sandoz Nutrition Ltd. | Improvements in or relating to organic compounds |
US5000975A (en) | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
EP0385859A1 (en) | 1989-03-01 | 1990-09-05 | Roberto Luis Dr. Ceriani | Composition for enhancing cancer therapy by administration of unsaturated fatty acids |
US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
JPH05503508A (en) | 1989-11-22 | 1993-06-10 | バーバル、エイドリアン | How to reduce blood cholesterol using arginine |
US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US5087472A (en) | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
US5492938A (en) | 1990-02-13 | 1996-02-20 | Martek Biosciences Corporation | Pharmaceutical composition and dietary supplement containing docosarexaenoic acid obtained from dinoflagellates |
US5167957A (en) | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
US5374657A (en) | 1991-01-24 | 1994-12-20 | Martek Corporation | Microbial oil mixtures and uses thereof |
US5550156A (en) | 1991-01-24 | 1996-08-27 | Martek Corporation | Microbial oil mixtures and uses thereof |
US5431928A (en) | 1991-03-18 | 1995-07-11 | Meiji Seika Kaisha, Ltd. | Feed for swine and method of breeding swine using the same |
US5171442A (en) | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
WO1994006417A1 (en) | 1992-09-16 | 1994-03-31 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
US5360613A (en) | 1992-09-16 | 1994-11-01 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
JPH07507569A (en) | 1992-12-23 | 1995-08-24 | アイオワ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | How to promote nitrogen retention in humans |
EP0637239A1 (en) | 1992-12-23 | 1995-02-08 | Iowa State University Research Foundation, Inc. | Method of promoting nitrogen retention in humans |
US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
EP0698078A1 (en) | 1993-05-13 | 1996-02-28 | Loders Croklaan Bv | Human milk fat replacers from interesterified blends of triglycerides |
US6596767B2 (en) | 1994-01-10 | 2003-07-22 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
US5780451A (en) | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
US6468987B1 (en) | 1994-04-01 | 2002-10-22 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US6060446A (en) | 1994-04-29 | 2000-05-09 | Wake Forest University | Method and composition for treating renal disease and failure |
US5726146A (en) | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US5834427A (en) | 1995-03-23 | 1998-11-10 | Sang Kee Han | Casein phosphopeptide, casein containing same and process for the preparation thereof |
US6099871A (en) | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
JPH09121809A (en) | 1995-08-03 | 1997-05-13 | B Braun Melsungen Ag | Prepared article for nutrition |
EP0756827A2 (en) | 1995-08-03 | 1997-02-05 | B. Braun Melsungen Ag | Composition for nutrition |
US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
US6340491B1 (en) | 1996-04-11 | 2002-01-22 | Loders Croklaan B.V. | Free flowing fat compositions |
JPH11508282A (en) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | Methods for preventing and treating cachexia and anorexia |
WO1998004253A1 (en) | 1996-07-26 | 1998-02-05 | Beale Paxton K | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
US7825084B2 (en) | 1996-08-12 | 2010-11-02 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
US6306908B1 (en) | 1997-02-21 | 2001-10-23 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
DE29709313U1 (en) | 1997-04-23 | 1997-09-11 | Kunz Armin | Preparation for muscle maintenance or to promote muscle building |
DE29707308U1 (en) | 1997-04-23 | 1997-06-26 | Kunz Armin | Preparation for muscle maintenance or to promote muscle building |
US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
US6371319B2 (en) | 1997-09-22 | 2002-04-16 | Abbott Laboratories | Closure system for containers |
US6096358A (en) | 1997-10-08 | 2000-08-01 | Abbott Laboratories | Method of manufacturing an aseptically sterilized package containing a liquid nutritional product |
US6103764A (en) | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
US20120283185A1 (en) | 1998-04-30 | 2012-11-08 | N.V. Nutricia | Food composition and method of using same |
US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
US6248909B1 (en) | 1998-06-19 | 2001-06-19 | Suntory Limited | Triglyceride and composition comprising the same |
US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
JP2002518440A (en) | 1998-06-23 | 2002-06-25 | アイオワ ステイト ユニヴァースティ リサーチ ファウンデイション インコーポレイテッド | Compositions and uses comprising β-hydroxy-β-methylbutyric acid and at least one amino acid |
WO1999066917A2 (en) | 1998-06-23 | 1999-12-29 | Iowa State University Research Foundation, Inc. | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
JP2002521428A (en) | 1998-07-30 | 2002-07-16 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Use of L-carnitine and its alkanoyl derivative for the manufacture of a medicament having anticancer activity |
WO2000015174A2 (en) | 1998-09-15 | 2000-03-23 | Korea Institute Of Science And Technology | Bioflavonoid as blood glucose level lowering agent |
US5976550A (en) | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
US20010008641A1 (en) | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
US6227261B1 (en) | 1998-12-24 | 2001-05-08 | Abbott Laboratories | Method and apparatus for the addition of sterile liquid to an aseptic system |
US6294206B1 (en) | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
WO2000000001A2 (en) | 1999-10-15 | 2000-01-06 | Phonak Ag | Binaural synchronisation |
US7795204B2 (en) | 1999-10-18 | 2010-09-14 | Northern Innovations And Formulations Corp. | Food supplement for increasing lean mass and strength |
US7517850B2 (en) | 1999-12-17 | 2009-04-14 | Carl Holt | Calcium phosphate nanoclusters and their applications |
US20060293220A1 (en) | 1999-12-17 | 2006-12-28 | Hannah Research Institude | Calcium phosphate nanoclusters and their applications |
WO2001056402A2 (en) | 2000-02-01 | 2001-08-09 | Muscletech Research And Development Inc. | Alpha lipoic acid based food supplement to increase lean muscle mass and strength |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6589576B2 (en) | 2000-02-04 | 2003-07-08 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
WO2001058284A1 (en) | 2000-02-10 | 2001-08-16 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
US6521591B1 (en) | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
US20030092609A1 (en) | 2000-02-23 | 2003-05-15 | Larsen Bjarne Due | Novel antiarrythmic peptides |
US20050075280A1 (en) | 2000-02-23 | 2005-04-07 | Larsen Bjarne Due | Novel antiarrythmic peptides |
WO2001077271A2 (en) | 2000-04-06 | 2001-10-18 | Conlinco, Inc. | Conjugated linoleic acid compositions |
JP2001288107A (en) | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | Reducing agent for adverse effect accompanied in cancer chemotherapy |
US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
US20050106219A1 (en) | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
US20020035965A1 (en) | 2000-08-03 | 2002-03-28 | Zehava Uni | Enhancement of development of oviparous species by in ovo feeding |
WO2002017735A2 (en) | 2000-08-29 | 2002-03-07 | Lonza Ag | Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
US20030203070A1 (en) | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
US7435442B2 (en) | 2000-10-20 | 2008-10-14 | Nutriz N.V. | Non-dairy products derived from rice and method of making |
US20030165604A1 (en) | 2001-02-15 | 2003-09-04 | Kazufumi Tsubaki | Products containing $g(b)-glucan |
US6749881B2 (en) | 2001-03-26 | 2004-06-15 | Kao Corporation | Packaged emulsified beverage |
US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
US20040202770A1 (en) | 2001-06-13 | 2004-10-14 | Cain Frederick William | Micronised fat particles |
US7648721B2 (en) | 2001-07-18 | 2010-01-19 | Dsm Ip Assets B.V. | Hydrolyzed milk proteins |
US20040237466A1 (en) | 2001-09-17 | 2004-12-02 | Holger Grossmann | Beverage bottling plant for filling bottles with a liquid beverage filling material, and a cleaning device for cleaning bottles in a beverage bottling plant |
US20040247755A1 (en) | 2001-09-21 | 2004-12-09 | Solvay Interox Gmbh | Stabilized hydrogen peroxide |
US20040248771A1 (en) | 2001-11-01 | 2004-12-09 | Giuseppe Raggi | Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
JP2003137790A (en) | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | Medicine including fructooligosaccharide including beta-2, 1 (beta 2 -> beta 1) bond-chain fructose oligomer as active ingredient |
US7247320B2 (en) | 2001-11-26 | 2007-07-24 | Nestec S.A. | Shelf stable nutritional composition containing intact whey protein, process of manufacture and use |
US7419596B2 (en) | 2001-12-12 | 2008-09-02 | Martek Biosciences Corporation | Extraction and winterization of lipids from oilseed and microbial sources |
US20030118703A1 (en) | 2001-12-12 | 2003-06-26 | Nguyen Minhthy Le | Methods and compositions for brightening the color of thermally processed nutritionals |
US20070125785A1 (en) | 2001-12-21 | 2007-06-07 | Robinson Clayton L | Closure for a Retort Processed Container Having a Peelable Seal |
WO2003053456A1 (en) | 2001-12-21 | 2003-07-03 | Phenion Gmbh & Co. Kg | Use of hyperforin or st john's wort extracts against anaphylactic states of shock and for maintaining and improving bone health |
WO2003091214A1 (en) | 2002-04-23 | 2003-11-06 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
US7498026B2 (en) | 2002-05-29 | 2009-03-03 | Danisco Us Inc., Genencor Division | Acyltransferase |
US20040013787A1 (en) | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
US20040220266A1 (en) | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040048925A1 (en) | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040106678A1 (en) | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US20040122210A1 (en) | 2002-10-14 | 2004-06-24 | Lars Thim | GLP-2 compounds, formulations, and uses thereof |
US7445807B2 (en) | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
US20040071825A1 (en) | 2002-10-15 | 2004-04-15 | Christopher Lockwood | Agglomerated granular protein-rich nutritional supplement |
WO2004064715A2 (en) | 2003-01-23 | 2004-08-05 | M N L Pharma Limited | Polyhydroxylated pyrrolizidine |
US7332178B2 (en) | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
WO2005000315A1 (en) | 2003-06-27 | 2005-01-06 | Bioprojet | Combination product comprising an antagonist or inverse agonist of histamine receptor h3 and an antipsychotic or antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |
US20080274230A1 (en) | 2003-10-14 | 2008-11-06 | Johns Paul W | Iron-Containing Human Milk Fortifier With Improved Antimicrobial Properties |
US20080058415A1 (en) | 2003-10-22 | 2008-03-06 | Avidor Shulman | Lipid Preparation for Enhancing Mineral Absorption |
US20080031860A1 (en) | 2003-12-24 | 2008-02-07 | N.V. Nutricia | Compositions Comprising Pantothenic Acid or Derivatives Thereof and Their Use for Stimulating Appetite |
US8217077B2 (en) | 2004-03-26 | 2012-07-10 | Abbott Laboratories | HMB uses thereof |
US20070093553A1 (en) | 2004-03-26 | 2007-04-26 | Baxter Jeffrey H | HMB compositions and uses thereof |
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
WO2005102301A2 (en) | 2004-03-26 | 2005-11-03 | Abbott Laboratories | Hydroxymethylbutyrate compositions and uses thereof |
US20050249650A1 (en) | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
US20090142425A1 (en) | 2004-07-24 | 2009-06-04 | Ralf Jager | Physiologically active composition |
US20060024385A1 (en) | 2004-07-27 | 2006-02-02 | Pedersen Mark A | Metabolic capacity enhancing compositions and methods for use in a mammal |
US20080260923A1 (en) | 2004-09-09 | 2008-10-23 | Nestec S.A. | Nutritional Products Having Improved Quality and Methods and Systems Regarding Same |
US20080305531A1 (en) | 2004-09-10 | 2008-12-11 | Verenium Corporation | Compositions and Methods for Making and Modifying Oils |
JP2006136318A (en) | 2004-10-15 | 2006-06-01 | Otsuka Pharmaceut Factory Inc | Method for producing liquid food |
WO2006062424A2 (en) | 2004-11-08 | 2006-06-15 | Sgp & Sons Ab | Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system |
US20060193961A1 (en) | 2005-02-25 | 2006-08-31 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
US20060204632A1 (en) | 2005-03-09 | 2006-09-14 | Bridget Barrett-Reis | Concentrated human milk fortifier liquid |
US20080193624A1 (en) | 2005-04-27 | 2008-08-14 | Enzymotec Ltd. | Human Milk Fat Substitutes |
US20060286210A1 (en) | 2005-06-06 | 2006-12-21 | Nagendra Rangavajla | Low-phytate infant formulas |
US20090220637A1 (en) | 2005-08-26 | 2009-09-03 | Nestec S.A. | Nutrition for obese patients |
EP1762147A1 (en) | 2005-09-09 | 2007-03-14 | Primalac Private Foundation | Nutritional concentrate for infants |
US20080254153A1 (en) | 2005-09-20 | 2008-10-16 | Junkuan Wang | Water Dispersible Composition and Method for Preparing Same |
WO2007066232A2 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
US20080317886A1 (en) | 2005-11-03 | 2008-12-25 | Sparkman Dennis R | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness |
EP2082738A1 (en) | 2005-12-19 | 2009-07-29 | Abbott Laboratories | Use of beta-hydroxy-beta-methylbutyrate to treat asthma |
EP1968564A2 (en) | 2005-12-19 | 2008-09-17 | Abbott Laboratories | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
CA2632262A1 (en) | 2005-12-19 | 2007-07-05 | Abbott Laboratories | Method of using .beta.-hydroxy-.beta.-methylbutyrate |
WO2007075605A2 (en) | 2005-12-19 | 2007-07-05 | Abbott Laboratories | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production |
AU2006331950A1 (en) | 2005-12-19 | 2007-07-05 | Abbott Laboratories | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production |
US20070142469A1 (en) | 2005-12-19 | 2007-06-21 | Thomas Debra L | Method of using beta-hydroxy-beta-methylbutyrate |
US20090087540A1 (en) | 2006-01-31 | 2009-04-02 | Nestec S.A. | Nutritional composition for low birth weight infants |
US20070219146A1 (en) | 2006-02-06 | 2007-09-20 | Sunil Bhaskaran | Synergistic Pharmaceutical And/Or Neutraceutical Flavanoid Composition For Management Of Diabetes Mellitus |
WO2007098092A2 (en) | 2006-02-21 | 2007-08-30 | Nutrijoy, Inc. | Food and beverage products with improved taste impressions |
US20080209864A1 (en) | 2006-06-05 | 2008-09-04 | Stuart Fergusson | Process and apparatus for forming a minimal headspace pouch |
US20080119552A1 (en) | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
WO2008115723A1 (en) | 2007-03-19 | 2008-09-25 | Atm Metabolics Lllp | Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid |
US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
US20090263367A1 (en) | 2008-04-18 | 2009-10-22 | Ryan Jason Foley | Composition and method for promoting internal health and external appearance |
CN101574146A (en) | 2008-05-07 | 2009-11-11 | 北京康比特体育科技股份有限公司 | Sports nutritional supplement containing HMB |
WO2009143097A1 (en) | 2008-05-21 | 2009-11-26 | Stokely-Van Camp, Inc. | Milk-based recovery beverage |
US20100074969A1 (en) | 2008-09-19 | 2010-03-25 | Unicity International, Inc. | Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix |
US20100179112A1 (en) | 2008-12-09 | 2010-07-15 | Metabolic Technologies, Inc. | Nutritional Intervention for Improving Muscular Function and Strength |
JP2009155336A (en) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | Treating agent |
CN101569412A (en) | 2009-06-01 | 2009-11-04 | 北京康比特体育科技股份有限公司 | Sports nutrition supplement and application thereof |
US20110218244A1 (en) | 2009-08-12 | 2011-09-08 | Kneller Bruce W | CREATINE ß-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
CN101703246A (en) | 2009-11-17 | 2010-05-12 | 卢惠强 | Exercise supplementation composition |
CA2784605A1 (en) | 2009-12-14 | 2011-06-23 | Olimp Laboratories Sp. Z O.O. | Isotonic beverage with chelates |
WO2011074995A1 (en) | 2009-12-14 | 2011-06-23 | Olimp Laboratories Sp. Z O.O. | Isotonic beverage with chelates |
WO2011094551A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Plastic packaged nutritonal liquids comprising hmb |
WO2011094544A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb and soluble protein |
WO2011094548A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
US20110250322A1 (en) | 2010-01-29 | 2011-10-13 | Paul Johns | Plastic Packaged Nutritional Liquids Comprising HMB |
US20110256272A1 (en) | 2010-01-29 | 2011-10-20 | Johns Paul W | Aseptically Packaged Nutritional Liquids Comprising HMB |
US20110256297A1 (en) | 2010-01-29 | 2011-10-20 | Johns Paul W | Nutritional Emulsions Comprising Calcium HMB and Soluble Protein |
US20110256301A1 (en) | 2010-01-29 | 2011-10-20 | Kensler Ann M | Nutritional Emulsions Comprising Calcium HMB |
US20110256299A1 (en) | 2010-01-29 | 2011-10-20 | Helmke Charles R | Nutritional Powders Comprising Spray Dried HMB |
US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
WO2011094557A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb |
EP2461704A1 (en) | 2010-01-29 | 2012-06-13 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
WO2011094549A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional powders comprising spray dried hmb |
WO2011156238A1 (en) | 2010-06-10 | 2011-12-15 | Abbott Laboratories | Substantially clear nutritional liquids comprising calcium hmb and soluble protein |
US20110305799A1 (en) | 2010-06-10 | 2011-12-15 | Abbott Laboratories | Substantially clear nutritional liquids comprising calcium hmb and soluble protein |
WO2012088075A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
WO2012097064A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
WO2012109105A1 (en) | 2011-02-07 | 2012-08-16 | Abbott Laboratories | Nutritional products comprising beta-hydroxy-beta-methylbutyrate |
WO2012112419A1 (en) | 2011-02-17 | 2012-08-23 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
CA2737972A1 (en) | 2011-04-07 | 2012-10-07 | Abbott Laboratories | Aseptically packaged nutritional concentrate |
US20120258209A1 (en) | 2011-04-07 | 2012-10-11 | Abbott Laboratories | Aseptically packaged nutritional concentrate |
Non-Patent Citations (387)
Title |
---|
"Lean DynamX", XP 002670342, available at http://www.fitpage.de/produicte/pd-1330122620.htm?categoryId=181 (last accessed Feb. 24, 2012) (5 pages). |
"Lite Protein Drink Mixes with GlycerLEAN, " database GNPD (Online) Mintel, Feb. 2002, XP002670335, available at www.gnpd.com. |
"Lite Protein Drinks", Database GNPD (Online) Mintel, Mar. 2000, XP002670334, available at gnpd.com. |
"Body Core Strength" ("Calorie Facts"), pub. online Apr. 25, 2010. http://web.archive.org/web/20100425070417/http://bodycorestrength.com/calorie-facts/. |
"Calorie Counter" (Calories in Infant Formula, Abbott Nutrition, Similac, Advance with iron, liquid concentrate, not reconstituted), pub. online Jan. 17, 2010. http://web.archive.org/web/20100117072138/http://acaloriecounter.com/food/infant-formula-abbott-nutrition-similac-advance-wth-iron-liquid-concentrated-not-reconstituted-formerly-ross-. |
"Milk Composition Proteins", "Milk Composition & Synthesis Resource Library", pub. online Oct. 19, 2009. http://web.archive.org/web/20091019072335/http://classes.ansci.illinois.edu/ansc438/milkcompsynth/milkcomp—protein.html. |
"Yahoo Answers" ("What age did you start giving your baby whole milk ?"), pub. online 2008. http://answers.yahoo.com/question/index?qid=20080819094659AA0urJT. |
Abbott, "HMB (Beta-hydroxy-beta-methylbutyrate): A Scientific Review," Apr. 2010, pp. 1-34, XP002670332, available at http://abbottnutrition.com/downloads/resourcecenter/hmb-a-scientific-review.pdf (last accessed Apr. 9, 2012). |
Aggarwal et al., "Suppression of the nuclear factor kB activation pathway by spice-derived phytochemicals: Reasoning for Seasoning", Annals of the New York Academy of Science, vol. 1030, pp. 434-441 (2004). |
AIDS Alert, 1999, vol. 14, No. 4, pp. 41-43. |
Alon et al., "Supplementing with beta-hydroxy-beta-methylbutyrate (HMB) to build and maintain muscle mass: a review," Research Communications in Molecular Pathology and Pharmacology, vol. 111 (1-4), pp. 139-151 (2002). |
Amendment A for U.S. Appl. No. 13/016,059 dated Jun. 25, 2012. |
Amendment A to U.S. Appl. No. 13/016,041 dated May 2, 2012. |
Amendment and Response to Office Action for U.S. Appl. No. 13/016,005 dated Jul. 29, 2013. |
Amendment and Response to Office Action for U.S. Appl. No. 13/151,911 dated Jul. 19, 2012. |
Amendment and Response with RCE for U.S. Appl. No. 13/016,005 dated Aug. 31, 2012. |
Amendment for U.S. Appl. No. 13/016,070 dated Mar. 7, 2013. |
Amendment from U.S. Appl. No. 13/151,911 dated Feb. 11, 2013. |
Amendment in U.S. Appl. No. 13/016,070 dated Apr. 7, 2014. |
Amendment to Office Action for U.S. Appl. No. 13/016,248 dated Feb. 7, 2013. |
Amendment with RCE for U.S. Appl. No. 13/016,041 dated Sep. 4, 2012. |
Amendment with RCE for U.S. Appl. No. 13/016,059 dated Apr. 20, 2015. |
Amendment with RCE for U.S. Appl. No. 13/016,070 dated Jul. 2, 2013. |
Amendment with RCE, Affidavit for U.S. Appl. No. 13/151,911 dated Oct. 18, 2013. |
Andela et al., "NFkappaB: A pivotal transcription factor in prostate cancer metastasis to bone," Clinical Orthopaedics and Related Research, vol. 415S, pp. S75-S85 (2003). |
Andrews, et al. "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," Nucleic Acids Research, vol., 19, No. 9, p. 2499 (1991). |
Anonymous, "Reload Dietary Supplements," Database GNPD (online) Mintel, May 2010, XP002676291 available at www.gnpd.com. |
ANONYMOUS: "HMB (beta-hydroxy-beta-methylbutyrate): A scienticif review", 1 April 2010 (2010-04-01), pages 1 - 34, XP002670332, Retrieved from the Internet <URL:http://abbottnutrition.com/downloads/resourcecenter/hmb-a-scientific-review.pdf> [retrieved on 20120224] |
ANONYMOUS: "Lean DynamX", 1 January 2003 (2003-01-01), pages 1 - 5, XP002670342, Retrieved from the Internet <URL:http://www.fitpage.de/produkte/pd-1330122620.htm?categoryId=181> [retrieved on 20120224] |
Appeal Brief for U.S. Appl. No. 13/016,005 dated Jan. 29, 2015. |
Appellant's Brief Under 37 CFR§ 41.37 dated Jun. 30, 2015 in U.S. Appl. No. 13/016,070. |
Applicant-Initiated Interview in U.S. Appl. No 13/440,610 dated Dec. 10, 2014. |
Applicant-Initiated Interview Summary and Advisory Action for U.S. Appl. No 13/151,911 dated Mar. 5, 2015. |
Applicant-Initiated Interview Summary for U.S. Appl. 13/016,005 dated Jul. 29, 2013. |
Applicant-Initiated Interview Summary for U.S. Appl. No. 13/016,005 dated Sep. 6, 2012. |
Applicant-Initiated Interview Summary for U.S. Appl. No. 13/016,041 dated Sep. 5, 2012. |
Applicant-Initiated Interview Summary in U.S. Appl. No. 13/016,005 dated Jun. 19, 2014. |
Ballard et al., "Effect of L-glutamine supplementation on impaired glucose regulation during intravenous lipid administration," Nutrition, vol. 12(5), pp. 349-354 (1996). |
Barber et al., "The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer", British Journal of Cancer, vol. 81, No. 1 pp. 80-86 (1999). |
Barnes et al. "NF kappa B: a pivotal role in asthma and a new target for therapy," Trends in Pharmacological Sciences, 1997, pp. 46-50 vol. 18. |
Battaini, "Protein kinase C isoforms as therapeutic targets in nervous system disease states," Pharmacological Research, vol. 44, No. 5, pp. 353-361 (2001). |
Beck et al., "Anticachectic and Antitumor Effect of Eicosapentaenoic Acid and its Effect on Protein Turnover," Cancer Research, vol. 51, pp. 6089-6093 (1991). |
Bibby et al., "Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals," Journal of the National Cancer Institute, vol. 78, No. 3 pp. 539-546 (1987). |
Brennan et al., "Nitrogen Metabolism in Cancer Patients," Cancer Treatment Reports, vol. 65, supplemental 5, pp. 67-78 (1981). |
Burke, R., "Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease," Pharm. and Therap., vol. 114 (3), pp. 261-277 (2007). |
Campbell, et al. "Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop" FASEB Journal, vol. 18, pp. 329-331 (2004). |
Carter "Protein Kinase C as a drug target: Implicaitons for drug or diet prevention and treatment of cancer," Current Drug Targets, vol. 12, No. 2, pp. 163-183 (2000). |
Case Study: Water Purification Plant Installed at New UK Power Station, Filtration and Separation (Dec. 2004). |
Charbonneau, "Recent case histories of food product-metal container interactions using scanning electron microscopy-x-ray microanalysis," Scanning, vol. 19(7), pp. 512-518 (1997). |
Choi, et al., "Hematein inhibits atherosclerosis by inhibition of reactive oxygen generation and NF-kappB-dependent inflammatory mediators in hyperlipidemic mice," Journal of Cardiovascular Pharmacology, 2003, vol. 42(2), pp. 287-295. |
Clark, RH et al., "Nutritional Treatment for Acquired Immunodeficiency Virus-Associated Wasting Using Beta-Hydroxy Beta-Methylbutyrate, Glutamine and Arginine: a Randomized, Double-Blind, Placebo-Controlled Study," J. Parenter Enteral Nutr. 2000; 24 (3) 133-139. |
Clinical Infectious Diseases, vol. 25(2), p. 457 (1997). |
Coffman et al., "Syntheses by Free-radical Reactions. V. a New Synthesis of Carboxylic Acids," Journal of the American Chemical Society , vol. 80, pp. 2282-2887 (1958). |
Communication from EP Application No. 11705725.7 dated Jan. 24, 2014. |
Communication from EP Application No. 11705725.7 dated Sep. 5, 2012. |
Communication from EP Application No. 11707733.9 dated Sep. 5, 2012. |
Communication in EP Application No. 11726580.1 dated Dec. 10, 2013. |
Communication in EP Application No. 11726580.1 dated Mar. 24, 2014. |
Damjanac et al., "Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease," Neurobiology of Disease, vol. 29(2), pp. 354-367 (2008). |
DATABASE GNDP MINTEL; 1 May 2010 (2010-05-01), ANONYMOUS: "RELOAD DIETARY SUPPLEMENTS", XP002676291, Database accession no. 1315326 |
DATABASE GNPD Mintel; 1 February 2002 (2002-02-01), ANONYMOUS: "Protein Drink Mixes with GlycerLEAN", XP002670335, Database accession no. 10102409 |
DATABASE GNPD Mintel; 1 March 2000 (2000-03-01), ANONYMOUS 03: "Lite Protein Drinks", XP002670334 |
De Los Reyes, et al., "Overview of resistance training, diet, hormone replacement and nutritional supplements on age-related sarcopenia-a minireview," Res. Comm. in Mol. Path. and Pharm., vol. 113-114, pp. 159-170 (2003). |
de Maat, et al., "Inflammation, Thrombosis and Atherosclerosis: Results of the Glostrup Study," Journal of Thrombosis and Haemostasis, 2003, vol. 1, No. 5, pp. 950-957. |
Decision of Rejection for CN Application No. 20118007418.x dated Jan. 16, 2015. |
Decision of Rejection for JP Application No. 2012-551324 dated Apr. 7, 2015 (English translation received May 20, 2015). |
Decision to Grant in EP Application No. 11705722.4 dated Apr. 25, 2014. |
Decision to Grant in EP Application No. 11705724.0 dated Jun. 13, 2013. |
Decision to Grant in EP Application No. 11705725.7 dated Dec. 18, 2014. |
Decision to Grant in EP Application No. 11707733.9 dated May 15, 2014. |
Decision to Grant in EP Application No. 11726580.1 dated Feb. 5, 2015. |
Delfino, "Hormonal regulation of the NF-kappaB signaling pathway", Molecular and Cellular Endocrinology, vol. 157, Nos. 1-2, pp. 1-9 (1999). |
Dentener et al., "Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations," Thorax, vol. 56, No. 9, pp. 721-726 (2001). |
EESR in EP 14169084.2 dated Sep. 22, 2014. |
Elam et al., "Effects of arginine and ornithine on strength, lean body mass and urinary hydroxyproline in adult males," Journal of Sports Medicine and Physical Fitness, vol. 29(1), pp. 52-56 (1989). |
Engel, et al., "Evolution of the Composition of a Selected Bitter Camembert Cheese during Ripening: Release and Migration of Taste-Active Compounds," Journal of Agricultural and Food Chemistry, vol. 49, pp. 2940-2947 (2001). |
Engel, et al., "Evolution of the Taste of a Bitter Camembert Cheese During Ripening: Characterization of a Matrix Effect," Journal of Agricultural and Food Chemistry, vol. 49, pp. 2930-2939 (2001). |
English translation for First Office Action for CN Application No. 201180007700.8 dated May 28, 2013 (received Jul. 10, 2013). |
English translation of 1st Office Action for Chinese Application No. 201180006376.8 dated May 13, 2013. |
English translation of 2nd Office Action in Chinese Application No. 201180006376.8 dated Jan. 13, 2014. |
English translation of Decision on Rejection for Chinese Application No. 20118007700.8 dated May 4, 2015. |
English translation of First Office Action for Chinese Application No. 201180007418.x (PCT/US2011/022938) dated Jun. 7, 2013. |
English translation of First Office Action for Chinese Application No. 20118007420.7 (PCT/US2011/022932) dated Jun. 5, 2013 (received Jul. 5, 2013). |
English translation of First Office Action for CN Application No. 201180007682.3 dated May 31, 2013 (received Jul. 8, 2013). |
English translation of First Office Action for CN Application No. 201180028614.5 (PCT/US2011/039170) (05174) dated Oct. 11, 2013 (received Nov. 20, 2013). |
English translation of Fourth Office Action for Chinese Application No. 20118007420.7 dated Dec. 1, 2014. |
English translation of Notice of Preliminary Rejection for Korean Application No. 10-2006-7022383 dated Feb. 13, 2012. |
English translation of notice of rejection in Japanese Application No. 2000-555603 dated Mar. 6, 2012. |
English translation of Office Action and Search Report in TW Application No. 100103536 dated Jun. 30, 2014. |
English translation of Office action for Chinese Application No. 201110094963 dated Mar. 30, 2012. |
English translation of office action for Taiwan patent application No. 095147808 dated Mar. 21, 2012. |
English translation of Office Action in TW Application No. 100103533 dated May 6, 2015. |
English translation of Office Action in TW Application No. 100103537 dated May 8, 2015. |
English translation of Search Report in TW Application No. 100103533 dated Apr. 28, 2015. |
English translation of Search Report in TW Application No. 100103537 dated May 2, 2015. |
English translation of Second Office Action for Chinese Application No. 201180007700.8 dated Feb. 8, 2014 (received Mar. 13, 2014). |
English translation of Second Office Action for Chinese Application No. 20118007418.x (PCT/US2011/022938) dated Mar. 24, 2014. |
English translation of Second Office Action for Chinese Application No. 20118007420.7 dated Jan. 16, 2014. |
English translation of Second Office Action for CN Application No. 2011800286145 (PCT/US2011/039170) dated May 20, 2014 (received Jun. 9, 2014). |
English translation of second Office Action in TW Application No. 100103536 dated Oct. 17, 2014. |
English translation of Third Office Action for Chinese Application No. 20118007420.7 dated May 15, 2014. |
English translation of Third Office Action for Chinese Application No. 20118007700.8 dated Aug. 21, 2014 (received Sep. 25, 2014). |
English translation of Third Office Action for CN Application No. 201180028614.5 dated Sep. 29, 2014. |
Evans et al., "Expression and activation of protein kinase C in eosinophils after allergen challenge," Am J. Physiol. Lung Cell Mole Physiol, vol. 277, pp. 233-239 (1999). |
Examination Report for SG Application 201208825-8 dated Oct. 4, 2013. |
Examination Report for Vietnam Application No. 1-2006-01765 dated Aug. 18, 2011. |
Examination Report from Malaysian Appl. No. PI20082097 dated Jul. 29, 2011. |
Examination Report from New Zealand Appl. 568611 dated Apr. 13, 2010. |
Examination Report issued in New Zealand Application No. 599371 dated Apr. 20, 2012. |
Examiner's First Report from Australian Application No. 2006331950 dated Apr. 19, 2012. |
Examiner's First Report from New Zealand Application No. 593182 dated Jun. 3, 2011. |
Examiner's Second Report from New Zealand Appl. 568611 dated Jun. 3, 2011. |
Extended Search Report in EP Application No. 11187274.3 dated Jun. 28, 2012. |
Extended Search Report in EP Application No. 12382138.1 dated Oct. 16, 2012. |
Fenteany et al., "Lactacystin, proteasome function and cell fate", J Biol. Chem., 1998, pp. 8545-8548, vol. 273, No. 15. |
Ferrando et al., "Prolonged bed rest decreases skeletal muscle and whole body protein synthesis", Am J. Physiol., vol. 270, pp. E627-E633 (1996). |
Final Office action for U.S. Appl. No. 13/016,005 dated Sep. 12, 2013. |
Final office action for U.S. Appl. No. 13/016,041 dated Jun. 8, 2012. |
Final Office Action in U.S. Appl. No 13/440,610 dated Jan. 30, 2015. |
Final Office Action in U.S. Appl. No. 13/016,005 dated Apr. 10, 2014. |
Final Office Action in U.S. Appl. No. 13/016,005 dated Aug. 20, 2014. |
Final office action in U.S. Appl. No. 13/016,059 dated Jan. 20, 2015. |
Final Office Action in U.S. Appl. No. 13/016,070 dated Sep. 16, 2014. |
Final Office Action in U.S. Appl. No. 13/440,610 dated Dec. 6, 2013. |
Final rejection for U.S. Appl. No. 13/016,070 dated Apr. 4, 2013. |
First Examination Report in EP Application No. 11726580.1 dated Jan. 21, 2013. |
First Hearing Notice in Indian Application No. 1372/MUMNP/2008 dated Nov. 4, 2011. |
First Office Action from Chilean Application No. 192-2011 dated Apr. 24, 2013. |
First Substantive Examination Report for SA Application No. 111320139 received Dec. 19, 2013. |
Flakoll et al., "Effect of b-hydroxy-b-methylbutyrate, arginine and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women," Nutrition, vol. 20, pp. 445-451 (2004). |
Fligger, et al., "Arginine supplementation increases weight gain, depresses antibody production and alters circulating leukocyte profiles in preruminant calves without affecting plasma growth hormone concentrations," J. Anim. Sci., vol. 75, pp. 3019-3025 (1997). |
Frank, "Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors," American Journal of Opthamology, 2002 pp. 693-698, vol. 133, No. 5. |
Fuller, et al., "Decreasing male broiler mortality by feeding the leucine catabolite b-hydroxy-b-methylbutyrate," Poult. Sci. vol. 73, Supplemental 1, p. 93 (1994). |
Gacs et al., " Significance of Ca-Soap Formation for Calcium Absorption in the Rat," Gut, vol. 18, pp. 64-68 (1977). |
Gallagher et al., "B-hydroxy-b-methylbutyrate ingestion, Part 1: Effects on strength and fat free mass," Med. Sci. Sports Exercise, vol. 32, No. 12, pp. 2109-2115 (2000). |
Gallagher, et al. "B-hydroxy-b-methylbutyrate ingestion Part II: Effects on Hematology, hepatic and renal function," Med. Sci. Sports Exercise, vol. 32, No. 12, pp. 2116-2119 (2000). |
Gao Fucheng et al., "Microcapsulation granulation Technology," New and High Technology of Modern Food Engineering, China Light Industry Press, pp. 51-53 and 58 (May 31, 1997), with summary in English on final page. |
Gharsallaoui et al., "Applications of spray-drying in microencapsulation of food ingredients: an overview,", Food Research International, 40 (2007) pp. 1107-1121. |
Goekijan, "Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development," Current Medical Chemistry, vol. 6, No. 9, pp. 877-903 (1999). |
Golubitskii, et al. "Stability of Ascorbic Acid in Aqueous and Aqueous-Organic Solutions for Quantitative Determination," Journal of Analytical Chemistry, vol. 62, No. 8, pp. 742-747 (2007). |
Gomes-Marcondes et al., "Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor," British Journal of Cancer, vol. 86, No. 10, pp. 1628-1633 (2002). |
Google search—"How much fat is in skim milk ?"http://www.google.com/ . . . =how+much+fat+is+in+skim&gs . . . , last accessed May 3, 2013. |
Hanson, et al., "Seven days of muscle re-loading and voluntary wheel running following hindlimb suspension in mice restores running performance, muscled morphology and metrics of fatigue but not muscle strength," Muscle Res. Cell Motil., vol. 31, pp. 141-153 (2010). |
Hauber et al., "Expression of interleukin-4, interleukin-9 and interleukin-13 in perpheral blood mononuclear cells of cystic fibrosis patients with and without allergy," EXCLI Journal, vol. 5, pp. 209-216 (2006). |
Haumann, "Structured Lipids Allow Fat Tailoring," International News on Fats, Oils, and Related Materials, vol. 8 (10), pp. 1044-1011 (1997). |
Ho, et al. "Antioxidants, NFkappaB activation and diabetogenesis" Proceedings of the Society for Experimental Biology and Medicine, vol. 222, No. 3, pp. 205-213 (1999). |
http://www.pedialyte.com/thisispedialyte/variety.cfm dated Jul. 2004. |
http://www.pediasure.com/homepage.cfm dated Mar. 2005. |
Huai, Ming Yan, "Progress in 2-4 methionine hydroxy butyric acid (HMB)," Foreign Animal Husbandry (Pigs and Poultry), Jun. 25, 2003. |
Intention to Grant in EP Application No. 11705722.4 dated Jan. 3, 2014. |
Intention to Grant in EP Application No. 11705723.2 dated Apr. 25, 2013. |
Intention to Grant in EP Application No. 11705724.0 dated Nov. 29, 2012. |
Intention to Grant in EP Application No. 11705725.7 dated Jul. 11, 2014. |
Intention to Grant in EP Application No. 11707733.9 dated Dec. 18, 2013. |
Intention to Grant in EP Application No. 11726580.1 dated Sep. 18, 2014. |
International Preliminary Report on Patentability for International Application PCT/US2011/022938 dated Jan. 25, 2012. |
International Preliminary Report on Patentability for International Application PCT/US2011/022947 dated Feb. 15, 2012. |
International Search Report and Written Opinion for International Application No. PCT/US2012/023767 dated Jun. 6, 2012. |
International Search Report and Written Opinion for International Application No. PCT/US2012/024817 dated Jun. 6, 2012. |
International Search Report and Written Opinion for PCT/US2011/022928 dated May 23, 2011. |
International Search Report and Written Opinion for PCT/US2011/022932 dated May 23, 2011. |
International Search Report and Written Opinion for PCT/US2011/022935 dated May 23, 2011. |
International Search Report and Written Opinion for PCT/US2011/022938 dated May 23, 2011. |
International Search Report and Written Opinion for PCT/US2011/022947 dated May 23, 2011. |
International Search Report and Written Opinion for PCT/US2011/039170 dated Aug. 3, 2011. |
International Search Report and Written Opinion for PCT/US2011/066096 dated Mar. 14, 2012. |
International Search Report and Written Opinion for PCT/US2012/020941 dated Apr. 26, 2012. |
International Search Report and Written Opinion from PCT/US2006/048303 dated May 6, 2008. |
International Search Report from PCT/US2005/007951 dated Aug. 24, 2006. |
Jagoe, "What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?", Current Opinion in Clinical Nutrition and Metabolic Care, vol. 4, No. 3, pp. 183-190 (2001). |
Jarowski, et al., "Utility of fasting essential amino acid plasma levels in formulation of nutritionally adequate diets III: Lowering of rat serum cholesterol levels by lysine supplementation," Journal of Pharmaceutical Sciences, vol. 64(4), pp. 690-691 (1975). |
Jowko et al., "Creatine and b-hydroxy-b-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program," Nutrition, vol. 17, pp. 558-566 (2001). |
Juven product information, http://abbottnutrition.com/Products/Juven dated 2010 5 pages. |
Kaizen HMB, www.bodybuilding.com as of Dec. 29, 2004. |
Kisner, "The Nutrition of the Cancer Patient," Cancer Treatment Reports, vol. 65, supplemental 5, pp. 1-2 (1981). |
Knitter et al. "Effects of b-hydroxy-b-methylbutyrate on muscle damage after a prolonged run," Journal of Applied Physiology, vol. 89, pp. 1340-1344 (2000). |
Komasio et al., "Beta hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and suvival via the MAPK/ERK and PI13K/Akt pathways," Biochimica et Biophysica Acta Molecular Cell Research, vol. 1793(5), pp. 755-763 (2009). |
Kortebein et al., "Effect of 10 days of Bed Rest on Skeletal Muscle in Healthy Older Adults," JAMA, vol. 297, pp. 1772-1774 (2007). |
Kreider, et al. "Effect of Calcium Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation During Resistance-Training on Markers of Catabolism, Body Composition and Strength," International Journal of Sports Medicine, vol. 20, No. 8, pp. 503-509 (Nov. 1, 1999). |
Kritchevsky, "An international symposium on cancer cachexia, cytokines, and EPA: Introduction," Nutrition, Elsevier Inc., US vol. 12(1), p. S1 (1996). |
Kutsuzawa, et al. "Muscle energy metabolism and nutritional status in patients with chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 152, No. 2, pp. 647-652 (1995). |
Learning Zone-HMB, www.interactivenutrition.com as of Dec. 29, 2004. |
Lentsch et al., "Activation and Regulation of NFkB during Acute Inflammation", Clin. Chem. Lab. Med., vol. 37, No. 3, pp. 205-208 (1999). |
Levenhagen et al., "Arginine, Lysine and b-hydroxymethylbutyrate (HMB) Supplementation Enhances the Efficiency of Protein Synthesis in Elderly Females," Nutrition Week Abstracts, vol. 75, pp. 4115-4125 (2002). |
Lorite et al., "Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF)," British Journal of Cancer, vol. 85, No. 2, pp. 297-302 (2001). |
Macchi et al. "Influence of co-ingestion of glucose on b-hydroxy-b-methylbutyrate (HMB) metabolism in humans," FASEB J. p. A909 (1999). |
MacDonald et al., "Understanding and Managing Cancer Cachexia,", Journal of the American College of Surgeons, vol. 197(1), 2003, pp. 143-161. |
May, et al. "Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-betamethylbutyrate, arginine, and glutamine," American Journal of Surgery, vol. 183, No. 4, 2002, pp. 471-479. |
Meier, "Protein kinase C activation and its pharmacological inhibition in vascular disease", Vascular Medicine, vol. 5, No. 3, pp. 173-185 (2000). |
Meletis et al., "Natural Supports for Gaining and Maintaining Muscle Mass," Alternative and Complementary Therapies, pp. 257-263 (2005). |
MERCK Index No. 1862, 2003. |
MERCK Index No. 5198, 2003. |
MERCK Index No. 7355, 2003. |
MERCK Index No. 9908, 2003. |
MERCK Index No. 9975, 2003. |
MERCK Manual, "Starving and Wasting," 16th Ed., pp. 919-920 (1995). |
Miller et al., "The effect of intensive training and b-hydroxy-b-methylbutyrate (HMB) on the physiological response to exercise in horses" FASEB J. p. A290 (1997). |
Milne et al., "Do Routine Oral Protein and Energy Supplements Improve Survival and Reduce Length of Hospital Stay for Elderly People", 2002 Nutrition Week Abstracts, p. 412S (2002). |
Montanari et al., "Quality of Organic Coatings for Food Cans: Evaluation Techniques and Prospects of Improvement," Progress in Organic Coatings, vol. 29(1-4), pp. 159-165 (1996). |
Moscat, "NF-kappaB activation by protein kinase C isoforms and B-cell function" Embo Reports, vol. 4, No. 1 pp. 31-36 (2003). |
Moschini et al., "Effect of feeding b-hydroxy-b-methylbutyrate (HMB) on leucine and fat metabolism in mammary gland," FASEB J. p. A70 (1993). |
Nawa et al., "A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt/PKB," Cellular Signalling, vol. 20(3), pp. 493-505 (2008). |
Nissen et al. "Nutritional role of the leucine metabolite b-hydroxy-b-methylbutyrate (HMB)," Journal of Nutritional Biochemistry, vol. 8, pp. 300-311 (1997). |
Nissen et al., "b-hydroxy-b-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors," J. of Nutrition, vol. 130, pp. 1937-1945 (2000). |
Nissen et al., "Colostral milk fat percentage and pig performance are enhanced by feeding the leucine metabolite bhydroxy-b-methylbutyrate to sows," Journal of Animal Science, vol. 72, pp. 2331-2337 (1994). |
Nissen et al., "Effect of b-hydroxy-b-methylbutyrate (HMB) supplementation of strength and body composition of trained and untrained males undergoing intense resistance training," FASEB J. p. A287 (1996). |
Nissen et al., "Effect of dietary supplements on lean mass and strength gains with resistance exercise: A meta analysis," Journal of Applied Physiology, vol. 94, pp. 651-659 (2003). |
Nissen et al., "Effect of feeding b-hydroxy-b-methylbutyrate (HMB) on body composition and strength of women," FASEB J. p. A150(1997). |
Nissen et al., "Effect of leucine metabolite b-hydroxy-b-methylbutyrate on muscle metabolism during resistance-exercise training," Journal of Applied Physiology, vol. 81, No. 5, pp. 2095-2104 (1996). |
Nissen et al., "The effect of b-hydroxy-b-methylbutyrate on growth, mortality and carcass qualities of broiler chickens," Poultry Science, vol. 71, pp. 137-155 (1994). |
Nissen et al., "The effects of the leucine catabolite, b-hydroxy-b-methylbutyrate (HMB) on the growth and health of growing lambs," Journal of Animal Science, p. 243 (1994). |
Non Final Office Action for U.S. Appl. No. 13/016,005 dated Dec. 27, 2013. |
Non Final Office Action for U.S. Appl. No. 13/016,059 dated Jul. 16, 2014. |
Non final Office Action for U.S. Appl. No. 13/151,911 dated Jul. 14, 2014. |
Non final office action for U.S. Appl. No. 13/440,610 dated Sep. 3, 2014. |
Non-final office action for U.S. Appl. No. 13/016,005 dated Mar. 28, 2013. |
Non-final office action for U.S. Appl. No. 13/016,059 dated Mar. 23, 2012. |
Non-final office action for U.S. Appl. No. 13/016,070 dated Dec. 17, 2013. |
Non-final office action for U.S. Appl. No. 13/151,911 dated Apr. 19, 2012. |
Nonnecke, B. et al., "Leucine and its Catabolites After Mitogen-Stimulated DNA Synthesis by Bovine Lymphocytes," J. Nutr., 1991; 121:1665-1672. |
Notice of Abandonment for U.S. Appl. No. 13/016,041 dated Oct. 21, 2013. |
Notice of Allowance for U.S. Appl. No. 13/016,248 dated Apr. 22, 2013. |
Notice of Allowance in Canadian Application No. 2,785,524 dated Apr. 21, 2015. |
Notice of Allowance in EP Application No. 11705722.4 dated Nov. 15, 2012. |
Notice of Allowance in U.S. Appl. No 13/016,248 dated Oct. 7, 2014. |
Notice of Appeal in U.S. Appl. No. 13/016,005 dated Nov. 20, 2014. |
Notice of Appeal in U.S. Appl. No. 13/016,070 dated Jun. 2, 2015. |
O'Brian et al., "The tumor promoter receptor protein kinase C: A novel target for chemoprevention and therapy of human colon cancer", Prog. Clin. BioRes., vol. 391, pp. 117-120 (1995). |
Office Action dated Apr. 10, 2014 acknowledging entry of Mar. 20, 2014 response to Dec. 27, 2013 Office Action for U.S. Appl. No. 13/016,005. |
Office Action for CA Application No. 2,801,339 dated Feb. 27, 2015. |
Office action for U.S. Appl. No. 11/025,466 dated Apr. 14, 2010. |
Office action for U.S. Appl. No. 11/025,466 dated Apr. 6, 2011. |
Office action for U.S. Appl. No. 11/025,466 dated Aug. 17, 2007. |
Office action for U.S. Appl. No. 11/025,466 dated Dec. 5, 2008. |
Office action for U.S. Appl. No. 11/025,466 dated Feb. 10, 2012. |
Office action for U.S. Appl. No. 11/025,466 dated Jun. 25, 2009. |
Office action for U.S. Appl. No. 11/025,466 dated May 5, 2008. |
Office action for U.S. Appl. No. 11/025,466 dated Oct. 4, 2010. |
Office action for U.S. Appl. No. 11/025,466 dated Sep. 8, 2011. |
Office action for U.S. Appl. No. 11/641,978 dated Feb. 26, 2008. |
Office action for U.S. Appl. No. 11/641,978 dated Jun. 7, 2010. |
Office action for U.S. Appl. No. 11/641,978 dated Mar. 3, 2009. |
Office action for U.S. Appl. No. 11/641,978 dated Oct. 20, 2009. |
Office action for U.S. Appl. No. 13/016,005 dated Jan. 27, 2012. |
Office action for U.S. Appl. No. 13/016,005 dated Jun. 1, 2012. |
Office action for U.S. Appl. No. 13/016,041 dated Feb. 3, 2012. |
Office action for U.S. Appl. No. 13/016,070 dated Dec. 18, 2012. |
Office Action for U.S. Appl. No. 13/151,911 dated Apr. 13, 2015. |
Office Action for U.S. Appl. No. 13/151,911 dated Nov. 6, 2014. |
Office Action for U.S. Appl. No. 13/440,610 dated May 9, 2013. |
Office action from Chinese Application No. 200580009596.0 dated Jun. 28, 2010. |
Office action from Chinese Application No. 200580009596.0 dated Jun. 9, 2011. |
Office action from Chinese Application No. 200580009596.0 dated Mar. 1, 2012. |
Office action from Chinese Application No. 200680047936.3 dated Feb. 24, 2011. |
Office action from Chinese Application No. 200680047936.3 dated May 25, 2010. |
Office action from Indian Application No. 1372/MUMNP/2008 dated Sep. 23, 2010. |
Office action from Japanese Application No. 2000-555603 dated Feb. 15, 2011. |
Office action from Japanese Application No. 2000-555603 dated Jan. 12, 2010. |
Office action from Japanese Application No. 2000-555603 dated Oct. 25, 2011. |
Office action from Japanese Application No. 2007-504991 dated Jun. 21, 2011. |
Office action from Russian Application No. 2008129605 dated Aug. 12, 2011. |
Office action from Russian Application No. 2008129605 dated Jul. 5, 2011. |
Office Action from U.S. Appl. No. 13/016,041 dated Apr. 1, 2013. |
Office Action from U.S. Appl. No. 13/151,911 dated Nov. 9, 2012. |
Office action in Canadian Application No. 2,785,524 dated Jul. 28, 2014. |
Office action in Canadian Application No. 2,785,526 dated Aug. 15, 2014. |
Office action in Canadian Application No. 2,801,339 dated May 26, 2014. |
Office Action in EP Application No. 11187274.3 dated Aug. 6, 2012. |
Office Action in JP Application No. 2012-551322 dated Aug. 5, 2014. |
Office Action in JP Application No. 2012-551324 dated Aug. 5, 2014. |
Office Action in JP Application No. 2012-551325 date Sep. 2, 2014. |
Office Action in JP Application No. 2012-551326 dated Sep. 2, 2014. |
Office Action in JP Application No. 2012-551329 dated Sep. 2, 2014. |
Office Action in JP Application No. 2013-514238 mailed Nov. 11, 2014. |
Office Action in MX Application No. MX/a/2012/008783 dated Sep. 12, 2014. |
Office Action in MX Application No. MX/a/2012/008785 mailed Aug. 29, 2014. |
Office Action in MX Application No. MX/a/2012/008786 mailed Sep. 3, 2014. |
Office action in Taiwan Application No. 094109357 dated Dec. 2, 2010. |
Office action in Taiwan Application No. 094109357 dated Jun. 24, 2011. |
Office Action in U.S. Appl. No 13/016,070 dated Mar. 3, 2015. |
Office Action in U.S. Appl. No. 13/016,070 dated May 21, 2014. |
Office action in U.S. Appl. No. 13/016,248 dated Nov. 7, 2012. |
Office action in U.S. Appl. No. 13/151,911 dated Jun. 7, 2013. |
Office action in U.S. Appl. No. 13/440,610 dated Apr. 11, 2013. |
Office action issued in Canadian Application No. 2,560,042 dated Nov. 14, 2011. |
Office action issued in Canadian Application No. 2,785,522 dated May 1, 2014. |
Office action issued in Canadian Application No. 2,785,523 dated May 21, 2014. |
Office action issued in Canadian Application No. 2,785,528 dated May 14, 2014. |
Office action issued in Phillipines Application No. 12006501893 dated Oct. 11, 2011. |
Office action issued in Phillipines Application No. 1-2008-501331 dated Apr. 4, 2012. |
Oliver, et al., "Airway smooth muscle and asthma," Allergology International, vol. 55, pp. 215-223 (2006). |
Orino, et al., "ATP dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubiquitinated proteins in human HL-60 cells," FESB Letters, vol. 284, No. 2, pp. 206-210 (1991). |
Ostasweski et al, "The effect of the leucine metabolite 3-hydroxy-3-methylbutyrate (HMB) on muscle protein synthesis and protein breakdown in chick and rat muscle," Journal of Animal Science, vol. 74, Supplemental 1, p. 138 (1996). |
Ostasweski et al. "Dietary supplementation of 3-hydroxy-3-methylbutyrate improved catch up growth in underfed lambs," Ann. Zootech. vol. 43, p. 308 (1994). |
Ostasweski et al. "The leucine metabolite 3-hydroxy-3-methybutyrate (HMB) modifies protein turnover in muscles of laboratory rats and domestic chickens in vitro," Journal of Animal Physiology and Animal Nutrition, vol. 84, pp. 1-8 (2000). |
Ostasweski, P. et al, "The Immunomodulating Activity of Dietary 3-hydroxy-3methylbutyrate (HMB) in Weaning Pigs", J. Anim. Sci. 1998; 76 (Suppl. 1):136. |
Ostaszewski, et al., "3-hydroxy-3methylbutyrated and 2-oxoisocaproate effect body composition and cholesterol concentration in rabbits," Journal of Animal Physiology and Animal Nutrition, vol. 79, pp. 135-145 (1998). |
Ostaszewski, P. et al., "3-hydroxy-3-methylbutyric acid (HMB) in Immunological Reactions Generated by Nutritional Allergy in Guinea Pigs," Veterinary Medicine 51(2), 1995, pp. 100-102. |
Ostaszewski, P. et al., 3-Hydroxy-3 Methylbutyrate (HMB) Fed in the Water Enhance Immune Response in Young Broilers, Abstract 96, 25 1998. |
Panton et al. "Effect of b-hydroxy-b-methylbutyrate and resistance training on strength and functional ability in the elderly," Medicine and Science in Sports and Exercise, p. S194 (1998). |
Panton et al., "Nutritional supplementation of the leucine metabolite b-hydroxy-b-methylbutyrate (HMB) during resistance training," Nutrition, vol. 16, pp. 734-739 (2000). |
Papet, et al., "The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs," British Journal of Nutrition, vol. 77, pp. 885-896 (1997). |
Perkins, et al. "Good cop, bad cop: the different faces of NF-kB," Cell Death and Differentiation, vol. 13, pp. 759-772 (2006). |
Peterson, A. et al., "Enhancement of Cellular and Humoral Immunity in Young Broilers by the Dietary Supplementation of B-Hydroxy-B-Methylbutyrate," Immunopharmacology and Immunotoxicity, 1999, 21(2), 307-330. |
Peterson, A. et al., "In Vitro Exposure with B-Hydroxy-B-Methylbutyrate Enhances Chicken Macrophage Growth and Function," Veterinary Immunology and Immunopathology, 1999 67:67-68. |
Portal et al., "Effect of HMB supplementation on body composition, fitness, hormonal profile and muscle damage indices," J. of Ped. Endo. & Meta., vol. 23(7), pp. 641-650 (2010). |
Porter, CM et al., "Sustained NFAT Signaling Promotes a Th1-Like Pattern of Gene Expression in Primary Murine CD4+Tcells," J. of Immunology, 2002: 168: 4936-4945. |
Pusptiasari et al., "Calcium Fortification of Cottage Cheese with Hydrocolloid Control of Bitter Flavor Defects", Journal of Dairy Science, vol. 74, pp. 1-7 (1991). |
Rathmacher et al., Safety of a nutritional mixture of b-hydroxy-b-methylbutyrate (HMB), glutamine and arginine in healthy young adults and patients with AIDS, JPEN 23(1): S10 (1999). |
Rathmacher, et al. "The Effect of the leucine metabolite b-hydroxy-b-methylbutyrate on lean body mass and muscle strength during prolonged bedrest" FASEB J. p. A909 (1999). |
Rathmacher, et al., "Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine and glutamine is safe and could improve hematological parameters," J. of Parenteral and Enternal Nutrition, vol. 28, No. 2, p. 6575 (2004). |
Reexamination Notice from Chinese Application No. 200580009596.0 dated Jul. 9, 2013. |
Request for Reconsideration after Non-Final Rejection in U.S. Appl. No 13/440,610 dated Jan. 5, 2015. |
Request for Reconsideration in U.S. Appl. No 13/016,070 dated Jan. 15, 2015. |
Response after Final with Terminal Disclaimer in U.S. Appl. No. 13/016,005 filed Dec. 9, 2013. |
Response for U.S. Appl. No. 13/016,059 dated Sep. 24, 2014. |
Response in U.S. Appl. No. 13/016,005 dated Aug. 6, 2014. |
Response to Mar. 5, 2015 Advisory Action for U.S. Appl. No 13/151,911 dated Mar. 6, 2015. |
Response to Notification of Non-Compliant Appeal Brief in U.S. Appl. No. 13/016,005 dated Apr. 2, 2015. |
Response to OA for U.S. Appl. No. 13/440,610 dated Aug. 9, 2013. |
Response to OA in U.S. Appl. No. 13/016,070 dated Aug. 19, 2014. |
Response to Office Action for U.S. Appl. No 13/151,911 dated Oct. 14, 2014. |
Response to office action for U.S. Appl. No 13/440,610 dated Apr. 23, 2013. |
Response to Office Action for U.S. Appl. No. 13/016,005 dated Apr. 27, 2012. |
Response to Office Action for U.S. Appl. No. 13/016,005 dated Mar. 20, 2014. |
Response with RCE in U.S. Appl. No 13/151,911 dated Feb. 20, 2015. |
Response with RCE in U.S. Appl. No. 13/440,610 dated Mar. 6, 2014. |
Rham et al., "Role of Ionic Environment in Insolubilization of Whey Protein During Heat Treatment of Whey Products," Journal of Dairy Science, vol. 67(5), pp. 939-949 (1984). |
Rowlands, et al., "Effects of b-hydroxy-b-methylbutyrate supplementation during resistance training on strength, body composition, and muscle damage in trained and untrained young men: a meta-analysis," J. of Strength and Conditioning Research, 23(3) 2009, pp. 836-846. |
Sandberg et al., "Effect of b-hydroxy-b-methylbutyrate on the physiological response to exercise and conditioning in horses," Journal of Animal Science, p. 198 (1997). |
Sandberg et al., "The effect of intensive training and b-hydroxy-b-methylbutyrate (HMB) on muscle glycogen concentration in the horse," J. of Animal Science, vol. 76, Supplemental 1, p. 175 (1998). |
Schols, "Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease," Thorax, vol. 51, No. 8, pp. 819-824 (1996). |
Schols, "Pulmonary cachexia," International Journal of Cardiology, vol. 85, No. 1 pp. 101-110 (2002). |
Search Report in EP Application No. 10186645.7-1216 dated Feb. 14, 2011. |
Search Report in EP Application No. 11187274.3 dated Feb. 15, 2012. |
Search Report in EP Application No. 12382138.1 dated Jun. 14, 2012. |
Second Hearing Notice in Indian Application No. 1372/MUMNP/2008 dated Mar. 10, 2012. |
Second Office Action for CN Application No. 201180007682.3 dated Mar. 18, 2014. |
Second Office action from Japanese Application No. 2007-504991 dated Mar. 13, 2012. |
Shen Hua, "Development in the aseptic package", China Packaging Industry Mar. 31, 2006 [English abstract]. |
Siu, et al. "Id2 and p53 participate in apoptosis during unloading-induced muscle atrophy", Am. J. Physiol. Cell. Physiol., vol. 288, C1058-C1073 (2005). |
Siwicki, A. et al., "Immunomodulating Effect of 3-Hydroxy-3-Methylbutyrate (HMB) on the Nonspecific Cellular and Humoral Defense Mechanisms in Rainbow Trout (Oncorhynchus mykiss)", J. Anim. Sci., 1998; 76 (Suppl. 1) 137. |
Siwicki, A. et al., "In VitroEffects of 3-Hydroxy-3-Methylbutyrate (HMB) on Measures of Immune Function and Immunocompetence in Fish", J.Anim.Sci., 1998: 76 (Suppl. 1) 136. |
Siwicki, A. et al., "Influence of 3-Hydroxy-3-Methylbutyrate (HMB) on Specific Cellular Immune Response After In Vitro and In Vivo Immunization with Yersinia ruckeri Antigen," J. Anim. Sci., 1998: 76 (Suppl. 1):136. |
Smart, et al., "Polyclonal and allergen-induced cytokine responses in adults with asthma: Resolution of asthma is associated with normalization of IFN-y-responses," Journal of Allergy and Clinical Immunology, vol. 110, pp. 450-456. |
Smith et al., "Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid" Cancer Research, vol. 59, No. 21, pp. 5507-5513 (1999). |
Smith et al., "Mechanisms of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate" Cancer Research, pp. 8731-8735 (2004). |
Smith et al., "Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes", British Journal of Cancer, vol. 89, No. 9, pp. 1783-1788 (2003). |
Smith, H. et al., "Attenuation of proteasome-induced proteolysis in skeletal muscle by beta-hydroxy-betamethylbutyrate in cancer-induced muscle loss," Cancer Research, 65(1), Jan. 2005, pp. 277-283. |
Sult, "Th1/Th2 Balance: A Natural Therapeutic Approach to Th2 Polarization in Allergy," Applied Nutritional Science Reports, vol. 676, pp. 1-8, 2003. |
Takabatake et al, "Circulating leptin in patients with chronic obstructive pulmonary disease,", American Journal of Respiratory and Critical Care Medicine, vol. 159, pp. 1215-1219 (1999). |
Talleyrand et al., "Uptake and output of the leucine metabolite b-hydroxy-b-methylbutyrate (HMB) across the legs of pigs," FASEB J., p. A71 (1993). |
Talleyrand, V. et al., "Effect of Feeding B-Hydroxyl-B-Methylbutyrate on Immune Function in Stressed Calves," FASEB J. 1994: 8:A951. |
Tanaka et al., "Effects of the novel Foxo 1 inhibitor AS1708727 on plasma glucose and trigyceride levels in diabetic db/db mice," Euro. Jour. of Pharm., vol. 645(1-3), pp. 185-191 (2010). |
Teixeira et al., "The role of interferon-c on immune and allergic responses, " Memorias do Instituto Oswaldo Cruz, vol. 100, (Suppl. 1) pp. 137-144 (2005). |
The Dairy Council ("The Nutritional Composition of Diary Products"), pub. online Jul. 2007—see pp. 3,5, and 7. The nutrional information from the 2002 summary edition of the Composition of Foods (Food Standards Agency (2002)) McCance and Widdowson's The Composition of Foods, 6th Summary Edition). |
Tisdale et al., "Inhibition of lipolysis and muscle protein degradation by epa in cancer cachexia," Nutrition, Elsevier Inc., US vol. 12(1), pp. S31-S33 (1996). |
Tisdale, et al., "Inhibition of Weight Loss by w-3 Fatty Acids in an Experimental Cachexia Model," Cancer Research, vol. 50, pp. 5022-5026 (1990). |
Todorov et al., "Characterization of a cancer cachectic factor," Nature, vol. 379, No. 6567, pp. 739-742 (1996). |
Todorov et al., "Induction of muscle protein degradation and weight loss by a tumor product," Cancer Research, vol. 56, No. 6, pp. 1256-1261 (1996). |
Toelstede et al. "Sensomics Mapping and Identification of the the Key Bitter Metabolites in Gouda Cheese," Journal of Agricultural and Food Chemistry, vol. 56, pp. 2795-2804 (2008). |
Toelstede et al., "Quantitative Studies and Taste Re-Engineering Experiments Toward the Decoding of the Nonvolatile Sensometabolome of Gouda Cheese," Journal of Agricultural and Food Chemistry, vol. 56, pp. 5299-5307 (2008). |
Toker, "Signaling through protein kinase C", Frontiers in Bioscience, vol. 3, pp. 1134-1147 (1998). |
Tordoff et al., "Vegetable bitterness is related to calcium content", Appetite, vol. 52, pp. 498-504 (2009). |
Translation of Notice of Rejection for Japanese Patent Application No. 2008-547409 dated Jun. 5, 2012. |
Van Koervering et al., "Effect of b-hydroxy-b-methylbuyrate on the health and performance of shipping stressed calves," The Oklahoma State Animal Science Research Report, pp. 312-316 (1993. |
Van Koevering et al., "Effects of b-hydroxy-b-methylbutyrate on performance and carcass quality of feedlot steers," J. of Animal Science, vol. 72, pp. 1927-1935 (1994). |
Van Koevering et al., "Oxidation of leucine and a-ketoisocaproate to b-hydroxy-b-methylbutyrate in vivo" American Journal of Physiology, pp. E27-E31 (1992). |
Von Bockelmann, Bernhard et al., "Aseptic Packaging of Liquid Food Products: A Literature Review", Journal of Agricultural and Food Chemistry, May 1986, vol. 34, issue 3, pp. 384-392. |
Vukovich, et al. "Body composition of 70-year old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults", Journal of Nutrition, vol. 131, No. 7, pp. 2049-2052 (2001). |
Vukovich, et al., "Effect of beta-hydroxy-beta-methylbutyrate on the onset of blood lactate accumulation and VO2 peak in endurance-trained cyclists," Journal of Strength and Conditioning Research, vol. 15, No. 4, pp. 491-497 (2001). |
Vukovich, et al., "The Effect of dietary b-hydroxy-b-methylbutyrate (HMB) on strength gains and body composition in older adults", FASEB J. p. A376 (19997). |
Waalkes, "A fluorometric method for the estimation of tyrosine in plasma and tissues," J. of Laboratory and Clinical Medicine, vol. 50, No. 51, pp. 733-736 (1957). |
Watchorn et al, "Proteolysis-inducing factor regulates hepatic gene expression via the transcription factor NFkappaB and STST3," FASEB Journal, vol. 15, No. 3, pp. 562-564 (2001). |
Whitehouse et al., "Increased expression of the ubiquitin-proteosome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB," British Journal of Cancer, vol. 89, No. 6, pp. 1116-1122 (2003). |
Whitehouse et al., "Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway," British Journal of Cancer, vol. 89, No. 4, pp. 737-745 (2003). |
Williams, et al., "Effect of a specialized amino acid mixture on human collagen deposition," Annals of Surgery, vol. 236, No. 3, pp. 369-375 (2002). |
Witte, et al., "Nutritional abnormalities contributing to cachexia in chronic illness", International Journal of Cardiology, vol. 85, pp. 23-31 (2002). |
Wolf et al., "The mitogen-activated protein kinase signaling cascade: from bench to bedside," IMAJ, vol. 4, No. 8, pp. 641-647 (2002). |
Written Opinion from PCT/US2005/007951 dated Oct. 6, 2006. |
Xu Sheng, "Evaluation of safety of hydrogen peroxide sterilization in aseptic packaging systems", Beverage Industry, vol. 9, Issue 7 Dec. 31, 2006 [English abstract]. |
Zachwieja, et al. "Effect of the Leucine Metabolite b-hydroxy-b-methylbutyrate on muscle protein synthesis during prolonged bedrest," FASEB Abstracts, p. A1025 (1999). |
Zarahevsky, et al. "Recovery of muscles of old rats after hindlimb immobilisation by external fixation is impaired compared with those of young rats," Exp. Gerontol., vol. 36, pp. 125-140 (2001). |
Zdychova et al., "Emerging role of Akt Kinase/Protein Kinase B signaling in pathophysiology of diabetes and its complications," Physiol. Res. vol. 54(1), pp. 1-16 (2005). |
Zhang et al., "Occurrence of beta-hydroxy-beta-methylbutyrate in foods and feeds," FASEB J. vol. 8(4-5) p. A464 (Abstract 2685) (1994). |
Zhang, et al., "Change in plasma b-hydroxy-b-methylbutyrate (HMB) by feeding leucine, a-ketoisocaproate and isovaleric acid to pigs," FASEB J., p. A392 (1993). |
Zuljdgeest-Van Leeuwen et al., "Inhibition of lipolysis by eicosapentaenoic acid in weight-losing cancer patients and healthy volunteers," Clinical Nutrition, Churchill Livingstone, London, GB vol. 17, p. 13 (1998). |
Also Published As
Publication number | Publication date |
---|---|
US20170295836A1 (en) | 2017-10-19 |
US20140030420A1 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2785524C (en) | Nutritional powders comprising spray dried beta-hydroxy-beta-methylbutyrate (hmb) | |
JP5892948B2 (en) | Nutritional emulsion containing calcium HMB | |
JP6033911B2 (en) | Nutritional emulsion containing calcium HMB and soluble protein | |
US9521859B2 (en) | Substantially clear nutritional liquids comprising calcium HMB and soluble protein | |
US20130337144A1 (en) | Nutritional products comprising calcium hmb and conjugated linoleic acid | |
US20190069590A1 (en) | Powdered nutritional formulations including spray-dried plant protein | |
US20170295836A1 (en) | Nutritional powders comprising spray dried hmb | |
CA2890223A1 (en) | Stabilized liquid nutritionals including insoluble calcium salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HELMKE, CHARLES;JOHNS, PAUL;KENSLER, ANN;SIGNING DATES FROM 20140107 TO 20140121;REEL/FRAME:032010/0546 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |